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During my PhD training I have extensively investigated the biological relevance of 
neutrophils in human colorectal cancer (CRC).  
This thesis consists of a first chapter that includes a general introduction covering important 
aspects related to development and functions of tumor infiltrating neutrophils (TANs). The 
following two chapters include a manuscript, currently being revised for publication, focusing 
on the interplay between neutrophils and CD8+ cells in CRC and a section reporting 
unpublished results concerning the impact of microbiota on neutrophils interaction with other 
non-transformed components of the CRC microenvironment. General discussion and 
perspectives are then reported in the final pages.  
Four publications resulting from my collaboration to additional projects of our research group, 
addressing the role of immune cells and stromal cells on CRC biology and clinical course are 
included with a brief introduction in the appendix. 
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Summary 
Colorectal cancer (CRC) represents a major cause of cancer related death in different 
geographic areas.  
Tumor infiltration by a variety of immune cell types has consistently been observed to be 
associated with favorable prognosis (1). In particular, CRC infiltration by CD8+ T cells 
expressing memory and activation markers has repeatedly been reported to represent a 
favorable prognostic marker, although underlying molecular mechanisms and the antigen 
specificity of these cells are largely unclear. In sharp contrast, tumor infiltration by myeloid 
cells has classically been associated with poor prognosis in a variety of cancers of different 
histological origin (2). However, recent reports underline that granulocytes might participate to 
anti-tumor immune responses in defined cancer types (3-5). In previous studies, our group has 
observed that CRC infiltration by myeloid cells expressing CD16 and myeloperoxidase (MPO) 
is also associated with good prognosis (6;7).  
Based on this background, I have addressed the role of granulocyte infiltration in CRC 
immunobiology. By using a clinically annotated tissue microarray (TMA) including over 650 
individual CRC, I have explored the prognostic significance of tumor infiltration by CD66b+ 
granulocytes. I found that CRC infiltration by CD66b+ granulocytes significantly correlates 
with favorable prognosis. Most importantly however, dense granulocyte infiltration 
significantly enhances the prognostic significance of CD8+ T cell infiltration in CRC. Taken 
together these data suggest that a cross-talk of potentially high clinical relevance takes place in 
CRC. Indeed, immunofluorescence staining of tissue sections from CRC showing evidence of 
infiltration by lymphocytes and granulocytes indicates that CD8+ and CD66b+ cells are 
frequently co-localized. Still unclear is whether neutrophils are able to modulate T-cell 
responsiveness to antigenic challenges (3;8). On the other hand activated T cells have 
previously been shown to enhance granulocyte survival and functions by the release of 
cytokines, including TNF-α, IFN-γ and GM-CSF (8).  
In additional studies I have extensively characterized phenotypic profiles of CRC infiltrating 
granulocytes, as compared to granulocytes from peripheral blood or infiltrating healthy mucosa 
adjacent to CRC. 
Functional studies performed by using tumor-derived and peripheral blood neutrophils indicate 
that these cells are able to efficiently co-stimulate CD8+ T cell activation induced by T-cell 
receptor (TCR) triggering, as witnessed by increased expression of CD69 activation marker, 
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proliferation and IFN-γ release. Furthermore, an expansion of cells expressing a “central 
memory” phenotypic profile was also observed in cultures stimulated in the presence of 
autologous neutrophils.  
Furthermore, importantly, malignant transformation in the intestinal mucosa is associated with 
early translocation of microorganisms from the gut lumen (9). A variety of bacterial strains 
including Bacteroides fragilis and Fusobacterium nucleatum have been found to be highly 
represented in CRC (10). Capitalizing on these data, I have investigated the potential 
significance of the interaction with bacterial strains associated with CRC in the elicitation of 
the anti-tumor effects of neutrophils. I found that interaction with Fusobacterium nucleatum 
rapidly induces apoptosis in neutrophils and abrogates their co-stimulatory capacity. Taken 
together, my results contribute to the identification of CRC microenvironment as typically 
characterized by a “ménage à trois”, including cancerous cells, the immune system and gut 
colonizing microorganisms. The nature of the reciprocal interaction of these actors and its 
outcome are likely to decisively impact on CRC development and progression. 
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1.  Human colorectal cancer 
Colorectal cancer (CRC) was characterized by a relatively low incidence only some decades 
ago. Nowadays however, it has become a predominant cancer type accounting for 
approximately 10% of cancer-related mortality and indeed represents the third most common 
cancer worldwide. CRC affects both sexes, and the majority of the cases occur in highly 
developed areas, including Australia, New Zealand, Northern America, Europe and Japan. In 
contrast a lower incidence of CRC is observed in Latin America, Africa and India. The main 
reasons explaining the higher incidence of CRC in the last decades and in the most 
industrialized regions of the world may include evolving dietary habits, physical inactivity, 
excess body weight and ageing populations (11). 
Genetic and environmental factors also play a crucial role into CRC incidence and development. 
Although the majority of CRC cases are sporadic, up to 20% of CRC patients have a positive 
family history. Most frequently hereditary CRC cancers are associated to the Lynch syndrome, 
characterized by mutations in one of DNA mismatch-repair genes: MLH1, MSH2, MSH6 or 
PMS2 (12). The second most common hereditary syndrome is caused by mutation in the 
adenomatous polyposis coli (APC) genes (13).  
Environmental and genetic factors promote the acquisition of hallmark characteristics of cancer 
in colon epithelial cells (14). Once these hallmarks are acquired, the progressive accumulation 
of epigenetic and genetic mutation leads to the activation of oncogenes and the neutralization 
of tumour suppressor genes. Therefore genomic instability may be considered as a trigger of 
the early neoplastic lesions in colon that could degenerate in cancer (15). Stem-like cells 
residing in the basis of the colon crypts have been suggested to represent CRC-initiating cells, 
essential for the generation and maintenance of the tumour. 
In the “classical” CRC formation model, cancers arise from an aberrant crypt, and evolve into 
early adenomas that may progress to advanced adenoma and, finally, colorectal cancers (16). 
Additionally, epigenetic alterations appear to cooperate with gene mutations driving cancer 
progression. DNA methylation alterations related to cancer development may include 
hypermethylation of CpG islands in gene promoters silencing tumour suppressor genes, and 
hypomethylation of repetitive genetic elements leading to genetic instability and oncogene 
activation. These molecular alteration frequently depend on the location of the tumour within 
the gastrointestinal (GI) tract, thus supporting the notion that specific micro environmental 
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features, including microbioma and stromal cell infiltration, may modulate disease 
development and progression (17).  
Based on molecular characteristics, CRC may be classified into four subgroups including 
hypermutable microsatellite stable, hypermutable microsatellite unstable, microsatellite stable 
or chromosome unstable, and CpG island methylator phenotype (CIMP) cancers. The various 
specific mutations that characterize the different subgroups are still largely under investigation, 
even though some of them are in common to all groups such as, for instance, those in APC, 
SMAD family member 4 (SMAD4) and catenin (CTNNB1) genes, KRAS and BRAF 
oncogenes, TP53 tumour suppressor genes and those involved in the WNT, RAS-RAF-MAPK, 
TGFβ and PI13-AKT pathway. 
Importantly, the development of colorectal cancer is also associated with the inflammatory 
bowel disease (IBD). Indeed the overall CRC risk for patients with IBD has been estimated 
between 4- to 20-fold (18) higher than in control subjects, although IBD explains only 1% of 
CRC in western populations.  
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1.2 Colorectal cancer prognosis  
CRC prognosis has slowly improved during the past decades. Routine staging relies on UICC-
tumor node metastasis (TNM) and American Joint Committee on Cancer criteria classification, 
representing the gold standard of prognostic factors in CRC. This classification still provides 
the basis for therapeutic decisions, even though the clinical course in individual patients is 
frequently poorly predictable (19).  
Overall, 5-year survival rates for patients with CRC are largely dependent on TNM stage (20) 
(Figure 1). However, in addition to TNM, a variety of tumour related features have been 
identified as essential prognostic factors. For instance, venous and lymphatic invasion represent 
important steps in the formation of metastases and, eventually, macroscopic tumour growth at 
a secondary site. Indeed, both these features were identified as independent adverse prognostic 
factors in multivariate analyses (21). 
Additional prognostic factors are represented by tumour grade (percentage of gland formation), 
tumor budding (transition from glandular structures to single cells beyond invasive margin) and 
tumor border configuration (infiltrative margin) (22-24). 
Remarkably however, patients with tumors with identical morphological features display an 
extensive heterogeneity in terms of clinical outcome. Microsatellite instability analysis gives 
important contributions regarding prognosis and therapeutic decision making in CRC. Indeed, 
previous studies have demonstrated that tumours with microsatellite instability hypermutability 
(MSI-H) show a significantly improved survival time as compared to microsatellite stable 
(MSS) CRCs. Moreover MSI-H phenotype may predict chemotherapy outcome. For instance, 
MSI-H CRCs do not appear to benefit from adjuvant therapy with fluorouracil but, instead, 
show an improved response to irinotecan-based chemotherapy. Finally, MSI is associated with 
high density tumor-infiltration by lymphocytes, possibly contributing to the improved 
prognosis of these patients (25-27).  
Since local immune cell infiltration has been shown to represent a potent prognostic factor, 
ongoing studies aim at developing immunoscores as novel instruments of CRC classification 
(see below). 
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Figure 1. Different classes of molecular and cellular biomarkers in CRC development stages. (Aghagolzadeh 
P. et al., World J Gastroenterol, 2016) 
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2. The tumour immune contexture  
Immune infiltrates are heterogeneous and very diverse in cancers of different histological origin 
and from patient to patient in cancers of similar origin. A large variety of immune cell types 
may be observed within tumour microenvironment, including dendritic cells, macrophages, 
mast cells, natural killer (NK) cells, neutrophils, naive and memory lymphocytes, B cells and 
T cells, including T helper 1 (TH1), TH2, TH17, regulatory T (Treg), and cytotoxic T cells 
(28;29). 
Immune cells may be located in the center of the tumour, or also in the invasive margins. Based 
on immune contexture, including density and functional orientation of infiltrating cells (29-31), 
studies in large annotated collections of human tumours have identified features associated with 
favorable or severe clinical course. Moreover, the role of chemokines and cytokines involved 
in shaping the immune contexture has also been investigated at the protein and gene level by 
bioinformatics tools.  
Variable numbers of infiltrating immune cells may be observed in different tumours of the same 
histological type, and in different locations within and around the tumour (Figure 2). Innate 
immune system cells, including myeloid cells such as neutrophils and macrophages infiltrating 
or surrounding tumour beds are frequently detectable both in the core and at the invasive front 
of the tumour. Immature dendritic cells are preferentially distributed in the tumour core, in 
contact with tumour cells or in the surrounding stroma, while mature dendritic cells are mainly 
concentrated in the adjacent tertiary lymphoid structures (TLS), in close contact with naive T 
cells (29). 
Lymphocytes are also not randomly distributed but located in specific areas. NK cells are 
usually found in the stroma and are not in contact with tumour cells. In contrast T cells, and 
particularly CD8+ T cells, are mostly located in the invasive margin although they can also be 
located in tumour core.  
Based on immune contexture evaluation, relatively simple scoring systems have been 
developed, and a high infiltration by CD3+/CD8+/CD45RO+ lymphocytes has consistently 
been reported to be associated with positive clinical outcomes (32). These data suggest that the 
interaction between cancer and immune system has significant implications for the clinical 
outcome and the identification of innovative prognostic markers, possibly also predicting 
responsiveness to chemo- and radiotherapy. 
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Figure 2. The immune contexture. Tumour anatomy showing features of the immune contexture, including 
tumour core, the invasive margin, tertiary lymphoid structures (TLS). The distribution of different immune cells 
is also shown. b | Table depicting the parameters of the immune contexture that predict a good prognosis. CT, core 
of the tumour; CTL, cytotoxic T lymphocytes; DC, dendritic cells; FDC, follicular dendritic cells; IFNγ, interferon-
γ; IL-12, interleukin-12; IM, invasive margin; IRF1, interferon regulatory factor 1; MDSC, myeloid-derived 
suppressor cells; NK cell, natural killer cells; TH, T helper cells; TReg cells, regulatory T cells. (Fridman W.H. et 
al., Nature Reviews Cancer, 2012). 
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Similarly to other cancer types, CRC is infiltrated by an extensive diversity of cells, including 
cancer associated  fibroblasts (CAFs), mesenchymal stem cells (MSCs), adipocytes, pericytes, 
endothelial cells (33) and immune cells that may change their role temporally and spatially 
within the tumour tissue (34). However, at difference from other tumors, the microenvironment 
of colorectal cancer is peculiar since during tumorigenesis microorganisms presented into the 
gut lumen may translocate through the epithelial barrier and enter in direct contact not only 
with tumor cells but also with immune cells creating a more complex scenario. To investigate 
how specific immune cells behave within this tumor scheme may lead to the development of 
new therapeutic strategies. 
2.1 Adaptive immunity and colorectal cancer 
Immune cells play important roles in CRC progression and even when the tumour becomes 
clinically detectable, adaptive immune response may play a crucial role in preventing cancer 
metastasis and recurrence (35) as observed in other tumour types, as well. 
CRC infiltration by various subsets of immune cells of the adaptive immune system, including 
CD8+CD45RO+, IRF-1+ memory T cells and FoxP3+ regulatory T cells, predicts prolonged 
patients’ survival (36). In particular Galon and his group have analyzed by gene expression and 
immunohistochemistry type, density and location of tumor associated lymphocytes (TILs) in 
an extensive numbers of CRC specimens.  They identified a prevalent cluster of Th1-related 
genes whose expression is inversely correlated with tumor recurrence. Moreover, by evaluating 
the level of CD3+, CD8+, CD45RO+ T cells and granzyme+ cell infiltration, they demonstrated 
that adaptive immunity promotes patients survival. Because T-cell infiltration is not spatially 
homogeneous in CRC, attention has been focused on the predictive values of T lymphocytes 
located in the center of the tumor (CT) and along the invasive margin (IM). The combined 
analysis of both tumor regions has improved the accuracy of survival predictions, as compared 
with single region analysis (36). 
Cytotoxic T lymphocytes (CTLs) are CD8+ cells representing one of the leading effector cell 
type in antitumor immunity by recognizing antigens expressed by tumor cells in association 
with HLA class I determinants (37). Upon triggering of their antigen specific T-cell receptor 
(TCR), CD8+ clonally expand and differentiate. Once activated, CD8+ cells are able to elicit 
“killer” lymphocyte functions, resulting in the destruction of tumor cells by either perforin and 
granzyme release or by Fas ligand-mediated mechanisms. Moreover CTLs also produce 
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cytokines, such as IFN inhibiting the proliferation of tumor cells and promoting their 
apoptosis.  
CD4+ T lymphocytes, responding to antigens restricted by HLA class II determinants, are also 
important for antitumor immunity. In particular, Th1 CD4+ T cells do produce IFN and TNF 
and support the proliferation of cytotoxic CD8+ cells by IL-2 release.  
Beneficial effects resulting from infiltration by immune cells of the adaptive immune system 
could persist during the tumor progression leading to a lower risk of metastasis. However, the 
immune reaction in tumors is much more complex and might include the recruitment of cells 
playing opposite effects. 
2.2 Innate immunity in colorectal cancer 
Several types of immunotherapy are taking advantage from the induction or exogenous 
administration of high numbers of CTLs. However, their use in the treatment of solid tumors is 
more limited, possibly due to the complexity of the tumor microenvironment which may 
strongly inhibit the elicitation of the cytotoxic effects of CD8+ cells. Therefore, the generation 
of tumor-specific CTLs may not suffice for the implementation of clinically effective anticancer 
immune responses. The investigation on the role of the other components of the tumor 
microenvironment is therefore essential (35). 
Macrophages are considered as one of the most abundant immune populations within the tumor-
microenvironment. Although various in vitro studies have shown that activated macrophages 
acquire the capacity to kill tumor cells, for instance by Fas ligand-dependent mechanisms, many 
studies have suggested that TAMs, conditioned by the tumor microenvironment, may exert pro-
tumor functions (38). Indeed a biological peculiarity of the macrophage lineage cells consists 
in their capacity to express different functional programs in response to various 
microenvironment stimuli. For instance during early stages of tumor growth, TAMs appear to 
have tumoricidal and antigen-presenting cells activity, and to produce inflammatory and Th1 
cytokines. In this phase TAMs are identified as classical M1-like cells (38). Subsequently, 
during tumor progression, macrophages may polarize towards an M2-like phenotype, 
supporting angiogenesis and  displaying immunosuppressive effects by producing soluble 
factors, such as IL-10 (39). Moreover, TGFβ production by TAMs has been shown to be 
involved in the ephitelial-to-mesenchymal transition (EMT) process frequently associated to 
metastasis formation (40). 
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Regarding their prognostic significance, in general terms, high density TAM infiltration has 
been consistently associated with unfavorable prognosis in a majority of tumor types (41;42). 
However, interestingly, their role in CRC is still controversial (43;44).  
Thus, although TAMs are considered as a promising immunotherapy target, the application of 
specific treatments to CRC has to wait for a more precise definition of their role. 
DC infiltration represents a significant prognostic factor in patients with CRC. In particular they 
appear to be more abundant during early stages of tumor progression (45). However, on the 
other hand, driven by tumor microenvironment, DCs may become functionally ineffective and 
promote tumor escape from immune response by failing to stimulate T lymphocytes.  
In addition to TAMs and DCs cells, functions and prognostic significance of CRC infiltration 
by other cell types of the innate immune system requires a more accurate analysis. Therefore 
during the last decade our group has started to explore these issues by using a clinically 
annotated tissue microarray (TMA) including over 1400 cases. 
First, we have shown that CRC infiltration by both CD56+NK cells and CD8+ T is associated 
with prolonged patient survival. In contrast, CRC infiltration by NK cells in combination with 
CD4+ lymphocytes has no detectable effect on the clinical outcome. These data may suggest a 
crosstalk between NK and CD8+ cells in the tumor microenvironment and provide a helpful 
prognostic information (46). Interestingly CRC is not the only tumor type where NK-CD8 
interplay impacts the overall survival of patients. For example in head and neck cancers it has 
been shown that NK cells activated by cetuximab cooperate with dendritic cells to trigger tumor 
antigen-specific T cell immunity (46).  However the functional role of NK cells has not been 
fully understood and whether CD56+ cells “per se” may represent a potentially positive 
prognostic marker still has to be elucidated.  
Subsequently, we observed that CRC infiltration by CD16+ myeloid cells is associated with 
favorable outcome. Interestingly, our flow-cytometry analysis indicates that CD16+ cells 
infiltrating CRC biopsy do not express CD56 and HLA-DR molecules. Therefore, we could 
speculate that NK, DCs and monocytes are not included in this CD16+ cells subset (7), which 
might rather comprise neutrophilic granulocytes. 
Based on these findings, our lab has developed a particular interest regarding the identification 
of neutrophils in patients with CRC. In initial studies, we observed that CRC infiltration by 
myeloperoxidase (MPO+) cells represents an independent marker of favorable prognosis. 
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Although the majority of the MPO+ cells are also CD66b+, we observed that MPO+ cells only 
represent a subset of CRC infiltrating CD66b+ neutrophils (6). 
In subsequent studies we have additionally observed that MPO+ and CD8+ T cells infiltrating 
CRC do not appear to synergize in determining a more favorable outcome, as compared with 
cancers showing MPOhigh/CD8low or MPOlow/CD8high infiltrates. It is tempting to speculate that 
CRC infiltration by these cell types might reflect different phases of immune response to CRC. 
However this data have contributed to the identification of a subgroup of CRC with a particular 
severe prognosis, characterized by MPOlow/CD8low tumor infiltration. Probably, patients 
bearing these cancers could be eligible for adjuvant treatments following surgery, irrespective 
of conventional TNM staging. (47). 
The role of neutrophils in CRC has not been explored in detail. Data from other groups suggest 
that high tumour infiltration by CD66+ neutrophils may correlate with either benign or poor 
prognosis in patients with CRC. In particular, in a cohort of East Asian patients (n=229) 
neutrophil infiltration was found to be associated with severe prognosis (48). Different genetic 
backgrounds in the cohorts of patients under investigation, e.g. from East Asia or Western 
Europe, could also play a role. Moreover, differences in gut microbiomes of patients from 
disparate geographic areas might also be involved.  
In contrast, most recently, neutrophil infiltration in CRC was reported to be associated with 
responsiveness to 5-fluorouracil (5FU) treatment (49).  Indeed, Jaillon et al have shown that 
CD66b is a reliable marker for the identification of TANs in CRC tissues. Indeed not all MPO+ 
cells are also CD66b+. Most importantly, they have observed that TAN density dramatically 
decreases in Stage IV patients as compared to Stage I-III (n=271). High TAN density was 
proposed to be associated with a favourable prognosis and prognostic significance could be 
influenced by clinical stage and 5FU-based chemotherapy.  
Since clinical significance of CRC infiltration by TAN is still largely unclear and functional 
mechanisms remain to be elucidated, I have addressed these issues in the context of my PhD 
project.  
Within the context of innate immunity, heterogeneous populations of immunosuppressive cells 
also need to be considered. In particular, myeloid derived suppressor cells (MDSC) have been 
indicated to be present in tumor and lymphoid tissues (50). These cells are much better 
characterized in murine models than in humans. In particular, in experimental animals, it has 
been shown that they may secrete various proangiogenic factors such as VEGF-A, PDGF-B, 
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FGF, metalloproteinases, and chemokines such as IL-8 within the tumor microenvironment 
(51;52). However, human MDSCs have not been studied in comparable detail, but rather 
identified as heterogeneous population of myeloid cells which may include immature 
granulocytes. Nevertheless MDSCs have been implicated in the resistance to antiangiogenic 
therapies in CRC (53) and high tumor infiltration has been suggested to be associated with poor 
prognosis (54;54-56). Therefore further investigation is warranted to identify new markers 
efficiently discriminating different populations within human MDSCs (57). 
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2.3 CRC immunotherapy 
Immunotherapy is frequently used either alone or in combination with chemotherapy for the 
treatment of a variety of cancers, including melanoma, lung cancers and hematological 
malignancies. Its use in CRC is currently being explored in different Institutions. Nowadays, 
CRC treatment generally consists of chemotherapy, anti-angiogenic treatments and epidermal 
growth factor receptor (EGFR) inhibitors. However, response to treatment is usually limited to 
a minority of patients and responding patients may develop resistance to the treatment. 
Therefore the development of innovative therapeutic approaches is urgently needed to improve 
clinical outcomes (58).  
Immune surveillance has been proposed as a process by which innate and adaptive immune 
systems together concur in detecting and destroying cancer cells. Immunomodulatory cells, 
cytokines, stromal cells from tumor microenvironment are involved in immune surveillance of 
CRC. However, the ability of the cancer cells to escape immune responses of the host has also 
been clearly documented. CRC cells not only evade immune response but may also manipulate 
the immune system to promote tumor growth and metastasis (59). 
Cytokines, monoclonal Abs, adaptive T cell therapies, peptide, protein or whole tumor cell and 
dendritic cell vaccines are included among immunotherapeutic strategies that have been 
clinically evaluated in Colorectal cancer. Even though, so far only therapeutic antibodies such 
as bevacizumab, aflibercept, cetuximab and panitumumab are FDA approved for CRC 
treatment (60;61). 
Peptide-based T-cell vaccines require identification of peptide epitopes recognized by T cells 
as tumor associated antigen. In this frame, carcinoembryonic antigen is the most frequently 
targeted antigen in CRC vaccine trials (62-64). Dendritic cells are potent APCs with a unique 
ability to present antigen and activate CD4+ and CD8+ T cells. They express all costimulatory 
molecules required for potent immune response. They are easily obtained from peripheral blood 
and hence they are widely used in the vaccine therapy trials for CRC treatment. 
Immune-checkpoint pathways modulate T-cell responses by influencing communication 
between T cells and antigen-presenting cells. They may be targeted by therapeutic monoclonal 
antibodies such as those recognizing programmed cell death-1 (PD1), PDL1 and CTLA-4. 
Studies with combinations of anti PD1 and anti VEGFR2 in mouse model of CRC resulted in 
dramatic inhibition of tumor growth (65). In contrast to melanoma, renal cancer, lung cancer, 
CRC cohorts have shown low response rates to PD-1, PDL-1 interaction blockade.  
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Overall, mismatch repair deficient tumors are highly infiltrated by CTL, displaying a high PD-
1 expression, thus suggesting that the immunotherapeutic interventions involving checkpoint 
blockade might be selectively effective in this important subset of cancer, and mismatch repair-
proficient might be much less responsive (66) (Figure 3). 
 
 
 
Figure 3. Schematic overview of immunotherapy in colorectal cancer. (Manik A.,et al Expert opinion on 
investigational Drugs, 2014)  
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3. Neutrophils in cancer  
 Neutrophils account for 50-70% of all leukocytes in humans and represent a first line defence 
against a variety of bacterial and fungal infections (67). Chemokines recruit neutrophils to the 
sites of infection/inflammation where they phagocytize and destroy bacteria by microbicidal 
activities, including release of reactive oxygen species (ROS), enzymes (MPO), and neutrophils 
extracellular traps (NET). 
In steady-state conditions, the bone marrow devotes about two-thirds of its space to the 
formation of neutrophils and monocytes (68). During granulopoiesis, neutrophils are generated 
as lymphoid-primed multipotential progenitors (LMPPs), further differentiating into 
granulocyte-monocyte myeloid progenitor (GMPs). Subsequently, they start a maturation 
process including progression through the following steps: myelobast, promyelocyte, 
myelocyte, metamyelocyte, band neutrophils and, lastly, segmented mature neutrophils (67) 
(Figure 4). During the different maturation steps, primary, secondary and tertiary granules are 
formed and stored together with defensive factors and enzymes, such as arginase, elastase and 
myeloperoxidase, crucial for the protection against infections. At difference with other immune 
cells, neutrophils are released by the bone marrow as terminally mature cells. However, atypical 
production of cytokines by tumour or stromal cells may affect the balance of neutrophils 
retention and release from bone marrow. For instance, in tumour-bearing mice the pressure on 
the bone morrow can be so intense to induce the release of immature neutrophils and this 
anomaly has also been noted in tumour patients (69) (Figure 3). The different composition of 
granules within immature neutrophils leads them to assume functions different from the mature 
subset and this may have profound consequences on tumour progression. By using density 
gradient purification it has been shown that different populations of neutrophils with diverse ex 
vivo properties can circulate within the same tumour-bearing mouse. Still unclear is whether 
these distinct populations are truly committed to divergent cell destiny or represent cells at 
diversified stages of maturation (69;70). Tumours share some basic chemotaxis mechanism 
coordinating neutrophils recruitment to inflammatory sites. For instance, tumour cells, together 
with stromal cells present in tumour microenvironment, produce diverse chemokines as 
CXCL8, CXCL1, CXCL5, CXCL2, and cytokines, GM-CSF, G-CSF IL-17 which do attract 
and activate neutrophils (71;72).  
So far, one of the reasons why neutrophils have not been recognized as important player into 
tumour microenvironment is related to their short life span. Currently it is known that 
circulating neutrophils life-span is around 7h in human and 8-10h in mice; in animal models 
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non-circulating neutrophils can survive in tissues for several days (73). However neutrophils 
may be longer retained in tumour tissues as compared to the spleen suggesting that specific 
microenvironments may support their survival locally and systemically. It is reasonable to 
speculate that neutrophils with a longer life span might have more time to synthesize new 
molecules and perform additional effector functions during tumour development (67). 
 
Figure 4. Tumour-induced emergency granulopoiesis. Tumours affect both the development and the release of 
bone marrow neutrophils. Tumour-induced increases in the levels of granulocyte-colony stimulating factor (G-
CSF) and granulocyte–macrophage-colony stimulating factor (GM-CSF) alter haematopoiesis towards production 
of myeloid cells, thereby increasing the generation of granulocyte–monocyte progenitors (GMPs) and neutrophil 
progenitors. In addition, tumours interfere with neutrophil retention in the bone marrow by upregulating various 
cytokines and chemokines. The composition of these mediators depends on the tumour type, mutations and oxygen 
levels in the tumour. Neutrophil-derived BV8 also induces neutrophil expansion. This pressure on the bone marrow 
induced by the tumour may result in increased generation and release of immature granulocytes. (Seth B. et al., 
Nature Reviews Cancer 2016).  
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Based on this background, many studies have highlighted the importance of tissue-resident 
neutrophils in oncology (74). In tumor-bearing mice, by analogy with polarized macrophages, 
tumor-associated neutrophils (TANs) have been classified in N1 and N2 (75). Similarly to M1, 
N1 are considered anti-tumorigenic  (TNFα high ICAM high,CCL3 high , arginase low) and, similarly 
to M2, N2 are considered pro-tumorigenic cells (TNFα low ICAM low,CCL3 low , arginase high 
MMP9 high VEGF high Fas low) (Figure 5). In particular, Fridlender has shown that transforming 
growth factor-b (TGFβ), can induce the N2 pro-tumor phenotype: indeed upon blocking of 
TGFβ, CD11b+ /Ly6G+ cells appear to be more segmented, capable to release pro-
inflammatory cytokines, and to impair tumour growth by their cytotoxicity ability. 
For example, in two murine cancer models (lung carcinoma and mesothelioma) neutrophils 
were found primarily at an early stage of tumor progression where they elicited their cytotoxic 
activity against tumor cells by releasing TNF and H2O2. Other mechanism inducing anti-
tumorigenic functions by TANs are represented by the production of tumor necrosis factor-
related apoptosis inducing ligand (TRAIL) (76) and the release of matrix metalloproteinase 
(MMP-8). Last but not least, neutrophils may modify recruit and activate T cell effector 
functions that are the main contributors to immune response against tumors (77). 
However, TANs may become more pro-tumorigenic during tumor progression. For instance 
activated neutrophils release arginase 1 (ARG1) able to degrade extracellular arginine, an 
amino acid playing an essential role in T cell activation. This may trigger immunosuppressive 
effects similar to those described for G-MDSC. Depletion of TANs in tumor bearing mice has 
been shown to increase the number of activated CD8+ cells resulting in the generation of 
smaller tumors (78). This may suggest that TANs can assume a different role based on the 
tumor microenvironment. However phenotypes and transcription factors regulating this 
polarization remain largely unknown. Moreover the study proposing N1, N2, terminology, 
characterized N1 as cells with hypersegmented nucleus and N2 as cells with banded or ring 
nucleus. Since morphology is a hallmark of neutrophils differentiation, it remains unclear 
whether N2 cells represent a subset of immature neutrophils or authentically different 
polarization state, leaving basically unresolved the relationship between maturation and 
polarization (78). Therefore N1 and N2 classification appears to be reductive, because a 
polarization could probably exists as a spectrum of different activations stages occurring within 
the tumor microenvironment (79). 
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Figure 5.  A simplified scheme of tumor-associated neutrophils (TAN) polarization. Neutrophils exert both 
anti-tumoral and pro-tumoral functions during cancer development and progression. This phenomenon is referred 
to as “neutrophil polarization” and is influenced by TGF-β and IFN-β cytokines. On this basis, neutrophils may 
serve as anti-tumoral effector cells by inducing cytotoxicity and by mediating tumor rejection and backing anti-
tumoral immune memory response (N1 phenotype). In contrast, neutrophils may also support tumor progression 
by promoting angiogenesis, invasion, metastasis and immune suppression (N2 phenotype). (Piccard H. et al., 
Critical Reviews in Oncology/Hematology 2012). 
 
A further complication to the picture of neutrophils subtypes is represented by the ongoing 
debate regarding the relationship between neutrophils and myeloid-derived-suppressor cells 
(MDSC) because is still unclear whether the latter they do indeed represent a distinct 
population. There is currently no way to uniquely distinguish MDSCs from neutrophils. 
However, an accurate comparison of mRNA profiles of naive neutrophils, G-MDSC and TANs 
has shown that TANs exhibit a completely different transcription programs, including up 
regulation of chemokines and cytokines genes, as compared to the other two subsets which, in 
contrast, appear to be more similar to each other (80). Importantly, recently differences in  
morphology, surface markers, functions and prognostic importance of the different tumor-
related circulating neutrophils have been proposed (81) (Figure 6). 
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Figure 6. Diversity in the morphology and function of murine circulating neutrophil sub-populations. The 
characteristics of the neutrophil sub-populations are shown. Nc1 (TEN)—HDN circulating neutrophils, Tumor 
entrained neutrophils; Nc2—mature LDN circulating neutrophils; G-MDSC—Granulocytic myeloid derived 
suppressor cells; N1 and N2 TAN—Tumor associated neutrophils. (Inbal M et al., Immunobiology 2016). 
 
Similarly to primary tumor growth, the role of neutrophils is also controversial in metastasis 
formation. It has been shown that CD11b+ cells are associated with priming of pre-metastatic 
lung cancer, and enhance the seeding of circulating tumor cells (82) by MMP-9 release.  
In fact, recent evidence suggests that neutrophils, upon stimulation by tumor–derived factors 
may contribute to a variety of steps conductive to cancer metastasis formation. As a matter of 
fact, neutrophils produce a large numbers of proteins able to support and facilitate tumor cell 
migration by remodeling extracellular matrix (ECM) through the release, immediately after 
activation, of a large intracellular pool of MMPs and serine proteases.  
Furthermore neutrophils have also been suggested to trigger epithelial-mesenchymal transition 
(EMT) of tumor cells by releasing TGF-β, a primary inducer of EMT, or through elastase 
degrading E-cadherin on tumor cells (83). Additional studies show that neutrophils are the 
major cell type recruited in primary tumors and mobilized to metastatic sites where they express 
a spectrum of different genes, particularly Bv8, G-CSF and S100A8. Accordingly, treatment 
with anti-Bv8 reduces lung metastasis formation (84) (Figure 7). Finally, other studies have 
confirmed the role of neutrophils in fostering metastatic niches and facilitating metastasis by 
suppressing CD8+ T cells proliferation and activation (85). 
Neutrophils may also use neutrophils extracellular traps (NETs) to sequester cancer cells 
promoting their adhesion to distant organs (86). 
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On the other hand, neutrophils have also been associated with anti-tumor and anti-metastatic 
potential in a lung mouse model (87) relying on cMet proto-oncogene (hepatocyte growth factor 
receptor) recruitment (88) (Figure 7). 
 
Figure 7. Neutrophil function in tumour initiation and growth. There are several mechanisms by which 
neutrophils either promote or limit tumorigenesis. Oncogenic transformation may be supported by the production 
of reactive oxygen species (ROS) and proteases. Promotion of tumour growth may also be mediated by crosstalk 
between neutrophils that are activated by tumour necrosis factor (TNF) and interleukin (IL)-17-producing CD4+ 
T cells. In addition to tumour initiation, neutrophils may promote progression of tumour growth by converting 
senescent cancer cells into proliferating cancer cells by IL-1 receptor antagonist (IL-1RA). Proliferation may be 
directly stimulated by transfer of neutrophil elastase (NE) to cancer cells. Neutrophils express inducible nitric 
oxide synthase (iNOS, also known as NOS2) or arginase (ARG1) suppressing CD8+ T cell-mediated anti-tumour 
immune responses. Immunosuppression can also be accomplished by transforming growth factor-β (TGFβ) 
activated neutrophils. In contrast, in defined contexts, neutrophils may also limit tumour growth. Upregulation of 
the hepatocyte growth factor receptor MET on neutrophils by endothelial cell-derived TNF may enhance their 
cytotoxic potential against cancer cells. Lastly, neutrophils participate in remodelling of the extracellular matrix 
(ECM) and induce angiogenesis by BV8 production and activation of vascular endothelial growth factor A 
(VEGFA) by matrix metalloproteinase 9 (MMP9). (Seth B. et al., Nature Reviews Cancer 2016). 
 
Despite their major relevance in the immune system, the role of neutrophils in the human 
tumor microenvironment has been largely neglected and direct analysis of TANs in patients 
with cancer has started to be addressed only in the last few years.  
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TANs could originate from either mature or immature cells. Common markers to identify 
neutrophils in tissues include CD66b (89;90) and CD15 (91). Moreover, TANs may also be 
identified by expression of functional molecules such as elastase (NE), (92) and 
myeloperoxidase (MPO) (6;93). The immunohistochemistry represents a valid tool to localize 
neutrophils in human cancer biopsies, it does not provide any information regarding the 
maturation and/or activation state of TANs.  
The existence of N1 and N2 polarized neutrophils has been postulated based on murine studies, 
but still unclear is whether a comparable analysis may apply to human cancers. Nevertheless, 
the clinical relevance of the interaction between neutrophils and cancer has recently begun to 
emerge (94). In particular, table 1 summarizes data addressing the role of neutrophils in 
peripheral blood and tumor tissue in clinical studies in different tumor types. It has been shown 
that TAN density can be correlated with poor prognosis, for instance in bronchoalveolar 
carcinoma (95) melanoma (96) renal carcinoma, head and neck squamous carcinoma (HNSCC) 
(97) liver carcinoma (98) and pancreatic adenocarcinoma (99). However, in CRC the potential 
role of neutrophils appears to be controversial (6). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer. 
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(Meixiao Shen et al., PLOS ONE, 2014). 
On the other hand, the neutrophils/lymphocyte ratio in the peripheral blood of patients with 
cancer may be considered as an additional prognostic marker. In general terms, the neutrophil-
to-lymphocyte ratio (NLR) is elevated in patients with more advanced or aggressive disease. 
Therefore a high NLR correlates with poor overall survival in many tumors (100;101). 
However, a high number of neutrophils in peripheral blood may also be associated with good 
prognosis, as, for instance, in gastric cancer (102). Thus, while the tumor microenvironment 
promotes the recruitment of neutrophils within the tumor, they might either control cancer 
progression or enhance it. 
Mechanisms underlying the prognostic significance of neutrophils are still far from being fully 
clarified. Nevertheless, their role has been addressed in detail in human lung cancer. Eruslanov 
et al have shown that neutrophils are able to promote T cell proliferation and interferon-gamma 
(IFN) release in a cell contact dependent manner in the earliest stages of lung cancer, 
suggesting that TANs are not “per se” immunosuppressive but rather capable of stimulating T 
cell responses. 
 30 
Moreover, they have demonstrated that TANs display a different phenotype and a different 
cytokines/chemokines profile as compared to peripheral blood neutrophils (PBNs). Based on 
these data, more recently, the same group has additionally identified a peculiar subtype of TANs 
exhibiting a hybrid phenotype and functional characteristics of neutrophils and antigen 
presenting cells (APC) such as macrophages and DCs. These APC-like, “hybrid” TANs are 
superior to canonical TANs in their ability to stimulate an anti-tumor T cell response. 
Importantly, the APC-like hybrid TANs were able to take up, degrade, and cross-present tumor 
antigens (103). 
In conclusion, neutrophils so far appear to be characterized by conflicting functions with pro- 
and anti-tumorigenic roles depending on tumor microenvironment and stages, with mechanisms 
still largely unclear. Thus, while functions and prognostic significance of tumor- associated 
neutrophils require further investigation and importantly, it is becoming more and more clear 
that TANs have been to be considered as important players in malignant disease.
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3.1 Neutrophils as therapeutic targets in cancer patients 
The variable functions of neutrophils in tumorigenesis may represent important therapeutic 
targets. Ongoing clinical trials in patients with cancer are targeting CXCR1 and CXCR2 to 
inhibit neutrophils trafficking and activation (104). Another pathway under investigation is 
represented by the IL-23/IL-17 axis. Neutrophils specific enzymes, known to promote tumor 
progression such as MMP9 and NE, may also be targeted for therapeutic purposes. Additional 
therapeutic strategies combine neutrophil targeting with standard treatments (105).  
An additional promising therapeutic approach is represented by the use of antitumor 
monoclonal antibodies (mAbs) to prompt the ADCC potential of neutrophils. Currently, new 
antibodies are being designed to enhance Fc receptors affinity and induce a stronger antitumor 
effect. In particular, FcαRI (CD89) appears to be the strongest inducer of ADCC by neutrophils. 
Therefore a new generation of cancer therapeutic biologicals could include IgA class antibodies 
to exploit neutrophils cytotoxicity (106). These advances urge the characterization of the 
polarization of neutrophils in the tumor microenvironment in order to envisage optimal 
therapeutic conditions. 
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4. Colorectal cancer and gut microbiome 
The gastrointestinal tract is populated by a huge amount of microorganisms. However, while 
the microbial load is about 101 cells per gram of content in the stomach, it raises to 1012 cells 
per gram in the colon. So far, an extensive number of studies have explored the link between 
microbiota and colorectal carcinogenesis. Alterations of host-microbiome interaction, usually 
referred to as dysbiosis, rather than infections by specific pathogens, appear to be associated 
with CRC development (107).  
However, still unclear is whether dysbiosis has to be considered causal or consequent to CRC 
development, and underlying mechanisms have not been elucidated, although immune and 
inflammatory responses are considered as fundamental factors leading to the alteration of 
microbial community. 
Numerous studies have compared the microbial community composition in patients with CRC 
and healthy subjects to attempt understanding modifications eventually occurring in the gut. 
Early events during CRC development may result in the loss of  the barrier function of the 
colonic epithelium, leading to the translocation of microorganisms products and enabling the 
colonization of the tumour microenvironment by invasive-adherent bacteria (108) (Figure 8).  
An extended list of “carcinogenic” bacteria supports the hypothesis that tumorigenesis is driven 
by mechanisms common to multiple bacterial groups rather than to individual microorganisms. 
Analysis of fecal samples has shown that Bacteroides fragilis, Enteroccocus feacalis, and 
adherent and invasive Escherichia coli colonization increase in patients with CRC as compared 
to the healthy controls. Most importantly, Fusobacterium nucleatum appears to be the bacterial 
strain most reproducibly associated with CRC (Figure 9). 
During the multistep development of CRC which is accompanied by morphological (barrier 
defects) and mutational (APC, K-RAS and p53 mutations) alterations, tumours may provide a 
selective pressure on bacteria, and particularly on anti-oncomicrobes which may subsequently 
be largely replaced by commensal gut bacteria as F.nucleatum (109). 
Intriguingly, two recent studies have shown that the microbial community may impact on 
efficacy of chemotherapeutic drugs, thereby highlighting the importance of the interaction 
among microbes, immune system and pharmaceutical interventions (110). 
Therefore, understanding the nature of microorganisms interfering with drug efficacy would be 
of prime importance for cancer therapy. The generation of microbiota signatures could allow 
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an optimal match of patients with chemotherapeutics drugs potentially leading to a personalized 
medicine based on the microbiota (111;112). As an example, some lactobacilli contribute to the 
generation of anti-tumour Th17 cells in cyclophosphamide CTX-treated mice (113). However, 
the same genus impairs CpG-oligodeoxynucleotides (CpG-ODN) efficacy (114). Furthermore, 
in murine models additional studies have also demonstrated that gut microbiota impact on DCs 
activation and anti-tumour T cell responses. 
 
 
Figure 8. A model of oral microbial activities in colon tumorigenesis. In this model, oral microbes such as 
F. nucleatum colonize gut epithelial surface. F. nucleatum may act as a bridging organism, allowing other oral 
microbes to bind via compatible adhesins. F. nucleatum and Porphyromonas can invade epithelial cells, disrupting 
signaling and promoting transformation. Oral microbes form a biofilm community altering epithelial tight 
junctions and promoting infiltration and inflammation from mucosal immune cells. Transformation of epithelial 
cells leads to an oncogenic synergy where host-secreted peptides feed asaccharolytic oral microbes, which in turn 
produce reactive oxygen species (ROS) and polyspermines, promoting both biofilm formation and continued 
inflammatory responses potentially promoting the tumor growth. (Kaitlin J, et al., Host-Microbe Biology, 2016). 
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Figure 9. 16s rDNA analysis of the colorectal cancer microbiome. Linear discriminant analysis (LDA) and 
effect size measurements identify Fusobacterium as the most differentially abundant taxon in CRC versus normal 
mucosa by 16S rDNA sequencing in 95 individuals. Tumor-enriched taxa are indicated with a positive LDA score 
(black), and taxa enriched in normal tissue have a negative score (gray). Clade data are represented in red for 
tumor-enriched taxa and blue for taxa enriched in normal tissue. The brightness of each dot is proportional to its 
effect size. (Kostic AD. et al., Genome Research, 2011).  
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4.1 CRC and Fusobacterium nucleatum 
 F. nucleatum (Fn) is a Gram-negative, opportunistic, obligated anaerobic bacterium. It is 
normally prevalent in the oral cavity, where it is involved in the pathogenesis of periodontitis. 
Therefore it is not a primary colonizer of the human gut. The epidemiology of acquisition or 
colonic colonization by Fn is unknown. In particular, whether the oral fusobacteria commonly 
associated with periodontal disease are in fact related to the Fn detected in the colon requires 
further investigation.  
Fn is a well-recognized pro-inflammatory bacterium and it has been found in IBD patients. 
Moreover, through complementary genomic methods analyzing the microbial associations of 
CRCs as compared to matched normal tissues, it has been shown that Fn might potentially 
contribute to CRC pathogenesis (115;116). These results were further supported by 
visualization of excess Fn by fluorescent in situ hybridization (FISH) on tumors as compared 
to corresponding normal colon tissue and by quantitative PCR analysis (118;119) 
Although Fusobacterium was not associated with defined tumor characteristics, it was found to 
be more abundant in CRC from Spain as compared to tumors from the United States and 
Vietnam. This suggests that Fusobacterium colonization may vary regionally, although the 
reasons for this, including different dietary habits, require further investigation. Recent data 
have provided experimental support for a tumor-inducing role of Fn. Chronic exposure of Apc 
Min/+ mice to Fn strains isolated from patients with IBD induced a modest, but significant, 
increase of CRC.  
More in detail, Fn was suggested to impact CRC growth by the activated complex of the FadA 
adhesin on its surface (117). In vitro colon carcinoma cell lines and tumor xenograft models 
revealed that FadA binds a select extracellular domain of E-cadherin on tumor cells surface, 
triggering invasion of the organism and the activation of -catenin/Wnt signaling promoting 
tumor growth. Furthermore, evaluation of tumor tissues from adenomas and adenocarcinomas 
as compared to normal colon tissue from healthy subjects revealed that FadA gene copy number 
was significantly higher in tumor tissues.  
Importantly, Fn has been shown to modulate immune responses. For example, recently, a study 
in 598 CRC cases has been shown that the amount of Fn in tumor tissues is inversely associated 
with CD3+ density (118). 
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In another study it has been demonstrated that Fap2 protein expressed by Fn inhibits tumor cell 
lysis by interacting with TIGIT receptor and thereby inhibiting the cytotoxic potential of NK 
and T cells. Based on this we may speculate that colorectal cancer exploits bacterial flora to 
evade immune evasion (119). 
Many bacteria such as B.fragilis are considered as oncomicrobes because they are capable of 
damaging colonic cells and induce their proliferation by releasing genotoxin. Whether Fn is 
able to synthesize genotoxin is still unclear but its peculiar metabolites and the presence of type 
Fap2 and RadD on its surface have been implicated in immune cell regulation (119).  
Finally, Fn colonization has been assessed as prognostic biomarker by correlating survival 
outcomes in CRC patients with bacterial load. A high amount of Fn in CRC is associated with 
poor patient survival (118). This finding supports the hypothesis that Fn colonization might 
promote a more biologically aggressive cancer subtype.  
Future investigations are warranted to explore potential influence of tissue colonization Fn on 
the effectiveness of T cell-based immunotherapies. 
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5. Rationale and aim of the thesis 
Colorectal cancer (CRC) remains the third cause of cancer-related mortality worldwide, and 
new therapeutic strategies are urgently needed. To this purpose, a better understanding of the 
different components within the tumour microenvironment is crucial. 
The immune landscape is of essential relevance in CRC clinical course. In particular, patients 
bearing tumours which are highly infiltrated by CD8+ and memory T cells have a higher 
probability of long term survival. In contrast, tumors infiltrated by myeloid cells have 
frequently been associated with poor prognosis in a variety of cancers of different histological 
origin. However, our group has previously observed that CRC infiltration by CD16+ myeloid 
cells, correlates with favorable outcome. Since these cells are HLA-class II- and largely MPO+, 
a neutrophil nature could reasonably be suspected. Recently, other groups have demonstrated 
that a high infiltration of CD66+ neutrophils may correlate with benign or poor prognosis in 
CRC patients.  
Based on these discrepancies, the prognostic significance of tumor associated neutrophils 
(TANs) infiltrating CRC has to be elucidated. Indeed, the biological significance of TANs in 
human cancer is poorly investigated and a major challenge is to clarify functional mechanisms 
potentially underlying the prognostic significance of TANs in CRC. 
Considering the current lack of understanding of neutrophil functions in tumour 
immunobiology, in this study we have investigated the prognostic relevance of CD66b cell 
infiltration in a large cohort of patients with CRC. Furthermore we have addressed the 
hypothesis of a possible crosstalk between peripheral blood neutrophils (PBN), TANs and 
CD8+ T cells in vitro and of its clinical significance in CRC showing combined infiltration by 
CD8+ T cells and neutrophils.  
Recent reports have documented that the gut microbiome is profoundly altered in CRC patients 
and specific microbial strains have been found to be associated with malignant transformation. 
In particular, the Gram-negative bacteria F. nucleatum appears to be enriched in CRC. This 
bacterial strain was shown to induce colitis-independent gut tumorigenesis in vivo and to cause 
the accumulation of myeloid cell subsets, in particular granulocytes, within the tumour mass. 
The role of these microbial strains in human CRC progression is currently under investigation. 
Whether specific microbial strains contribute to TANs phenotype and impair their interplay 
with other immune and stromal cells present in the tumour microenvironment is currently 
unknown. 
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Based on this background the main aim of my PhD project is to understand the role of 
neutrophils in human CRC immunobiology, and how different components of the tumour 
microenvironment impact on their functionality. 
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Abstract 
Purpose: Tumor infiltration by different T lymphocyte subsets is known to be associated with 
favorable prognosis in colorectal cancer (CRC). Still debated is the role of innate immune 
system. We investigated clinical relevance, phenotypes and functional features of CRC 
infiltrating CD66b+ neutrophils and their crosstalk with CD8+ T cells.  
Experimental design: CD66b+ and CD8+ cell infiltration was analyzed by 
immunohistochemistry on a tissue microarray including >650 evaluable CRC samples. 
Phenotypic profiles of tissue infiltrating and peripheral blood CD66b+ cells were evaluated by 
flow cytometry. CD66b+/ CD8+ cells crosstalk was investigated by in vitro experiments.  
Results: CD66b+ cell infiltration in CRC is significantly associated with increased survival. 
Interestingly, neutrophils frequently co-localize with CD8+ T cells in CRC. Functional studies 
indicate that although neutrophils are devoid of direct antitumor potential, co-culture with 
peripheral blood or tumor associated neutrophils (TANs) enhances CD8+ T cell activation, 
proliferation and cytokine release induced by suboptimal concentrations of anti-CD3 
monoclonal antibody (mAb). Moreover, under optimal activation conditions, CD8+ cells 
initially stimulated in the presence of CD66b+ cells show decreased expression of PD-1 
“exhaustion” marker and are significantly less susceptible to apoptosis induced by T- cell 
receptor triggered re-stimulation.  Importantly, combined tumor infiltration by CD66b+ and 
CD8+ T lymphocytes is associated with significantly better prognosis, as compared to CD8+ T 
cell infiltration alone.  
Conclusions: Neutrophils enhance the responsiveness of CD8+ T cells to TCR triggering. 
Accordingly, infiltration by neutrophils enhances the prognostic significance of CRC 
infiltration by CD8+ T cells, suggesting that they might effectively promote antitumor 
immunity.   
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1. Introduction 
Granulocytes account for 50-70% of all leukocytes in humans. They represent a first line 
defense against a variety of bacterial and fungal infections (1;2). However, their role in anti-
cancer immune responses is debated (1-3). A number of studies suggest that high 
granulocyte/lymphocyte ratios in peripheral blood are associated with poor prognosis in 
different malignancies (4). Furthermore, myeloid cells of the granulocytic lineage at different 
maturation stages have been shown to represent sizeable subsets of myeloid-derived suppressor 
cells (MDSC), promoting tumor growth and inhibiting cancer specific adaptive responses (5-
7).  
More recently, the possibility that neutrophils might promote anti-tumor immune responses of 
potential clinical relevance has started to be explored (2). In particular, the ability of neutrophil 
to polarize into N1 and N2 functional profiles, similarly to macrophages, has been documented 
in experimental models (8;9). Furthermore, tumor “educated” neutrophils were shown to elicit 
anti-metastatic effects (10) and the interaction of hepatocyte growth factor (HGF) with its 
receptor MET has been suggested to play a key role in the recruitment of neutrophils mediating 
anti-tumor activities (11). Most interestingly, earlier studies indicated that production of 
granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating 
factor (GM-CSF), promoting neutrophil survival and activation by tumor cells, could induce 
adaptive anti-tumor immune responses and regression of established tumors based on 
neutrophil-T cell interaction (12;13). Clinical studies have also been pursued. In particular, the 
ability of early stage lung cancer infiltrating neutrophils to support T cell proliferation and anti-
tumor responses has been demonstrated (14;15). However, their prognostic significance was 
not addressed. 
Colorectal cancer (CRC) represents the third cause of cancer-related mortality worldwide (16). 
TNM staging, routinely used to identify patients eligible for different treatments is frequently 
ineffective in predicting CRC clinical course (17).  
Clinical relevance of the composition of tumor infiltrate in CRC has been extensively 
investigated in the past decade (18). CRC infiltration by CD8+ and memory T cells has been 
consistently associated with favorable prognosis (19;20). The specificity of these cells is largely 
unclear. Recognition of differentiation antigens (21) or neo-antigens (22) expressed by tumor 
cells has been reported. Alternatively, bystander effects related to T cell responses against 
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antigens expressed by microbial commensal could also be hypothesized. Interestingly, 
expression of activation markers by CRC infiltrating lymphocytes was found to correlate with 
prolonged survival (23).  
The role of the innate immune system is still debated. NK cell infiltration is modest and apparently 
devoid of prognostic significance (24). Although tumor infiltration by myeloid cells has 
frequently been associated with poor prognosis in a variety of cancers (25), macrophage 
infiltration, has been suggested to correlate with favorable prognosis in CRC (26).  
The role of neutrophils has not been explored in comparable detail. We previously observed 
that CRC infiltration by CD16+ myeloid cells is associated with favorable outcome (27). 
Similarly to neutrophils, these cells are HLA-class II- and largely myeloperoxidase (MPO)+ 
(28). Data from other groups suggest that high tumor infiltration by CD66+ neutrophils may 
correlate with either benign or poor prognosis in patients with CRC. In particular, in a cohort 
of East Asian patients (n=229) neutrophil infiltration was found to be associated with severe 
prognosis (29). Moreover, neutrophil infiltration in lung metastases has been suggested to be 
associated with severe prognosis following surgical excision (30). In contrast, most recently, 
neutrophil infiltration in CRC was reported to be associated with responsiveness to 5-
fluorouracil (5FU) treatment (31). Thus, potential clinical significance of tumor associated 
neutrophils (TANs) infiltrating CRC is still unclear and underlying functional mechanisms 
remain to be elucidated.  
Here we have analyzed the prognostic significance of CRC infiltrating CD66b+ neutrophils by 
using a clinically annotated tissue microarray (TMA) including over 650 cases. In addition, we 
have comparatively evaluated phenotypes of neutrophils from healthy and cancerous colon 
tissues and peripheral blood from patients and healthy donors (HD). Their ability to support 
adaptive immune responses was also specifically addressed. Finally, the prognostic relevance 
of the association of neutrophils with CD8+ T cells infiltrating CRC microenvironment was 
explored. 
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2. Materials and methods 
2.1 Tissue Microarray construction  
The TMA used in this work was constructed by using >650 non-consecutive, formalin-fixed 
and paraffin-embedded primary CRC samples, from the tissue biobank of the Institute of 
Pathology of the University Hospital Basel (Switzerland), as previously described (27;32;33). 
A semi-automated tissue arrayer was used to transfer punches of a 0.6 mm diameter from tissue 
blocks onto glass slides. Punches were derived from the center of the tumors and consisted of 
at least 50% tumor cells. Clinical-pathological data for patients included in the TMA are 
summarized in Table 1. Use of clinical information was approved by local ethical authorities. 
2.2 Immunohistochemistry  
TMA slides were incubated with primary antibodies specific for CD8, CD16, MPO (23;27;28) 
and CD66b (clone G10F5, Biolegend). Secondary stainings and negative controls were 
performed as described (23;27;28). CRC infiltration by cells expressing defined markers was 
scored by experienced pathologists.  
2.3 Tumor cell lines  
Established human CRC cell lines (DLD1, HCT116, SW480, HT29, and SW620) were 
purchased from European Collection of Authenticated Cell Cultures (ECACC). DLD1 and 
HCT116 were cultured in RPMI-1640 supplemented with 10%  fetal bovine serum (FBS), 
GlutaMAX-I, nonessential amino acids (NEAA), 100 mM sodium pyruvate, 10 mM HEPES 
(all from GIBCO). HT29 cells were cultured in McCoy's 5A medium (Sigma-Aldrich), 
supplemented with 10% fetal bovine serum, GlutaMAX-I and kanamycin (GIBCO). SW480 
and SW620 cells were cultured in L15 medium (Sigma-Aldrich), supplemented with 10% FBS, 
GlutaMAX-I and Kanamycin (GIBCO). Absence of mycoplasma contamination in tumor cell 
lines was verified by PCR with mycoplasma-specific primers, prior to experimental procedures. 
2.4 Clinical specimen collection and processing 
Clinical specimens from consenting patients undergoing surgical treatment at Basel University 
Hospital, St. Claraspital Basel, and Ospedale Civico, Lugano (all in Switzerland), were obtained 
according to procedures approved by local ethical commissions. Tumor tissues and 
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corresponding tumor-free mucosa fragments were embedded in OCT for further histological 
evaluation or enzymatically digested by using an enzyme cocktail including 2 mg/mL 
collagenase IV (Worthington Biochemical Corporation) and 0.2 mg/mL DNAse I, (Sigma-
Aldrich for 1h at 37°C) to obtain single cell suspensions, as previously detailed (32). 
2.5 Neutrophil and lymphocyte isolation 
TANs were isolated from tumor cell suspensions by positive selection of CD66b+ cells with 
antibody coated microbeads according to the manufacturer’s instructions (Miltenyi Biotec). The 
purity as well as the viability of TAN obtained was tumor sample dependent (between 70% to 
90%, and about 20%-30% of Annexin V positive cells respectively). Peripheral blood was 
collected from patients with CRC prior to surgery or from healthy donors, and density-gradient 
centrifugation was performed. Sedimented fractions containing high-density neutrophils were 
washed and treated with dextran 4% (T500, Pharmacia) in saline solution and residual 
erythrocytes in supernatants were lysed by using lysis buffer (Miltenyi Biotec). Peripheral 
blood neutrophils (PBNs) were further enriched by positively removing contaminating cells, to 
reach 98% purity using the EasySep Human Neutrophil Enrichment Kit (Stemcell 
Technologies). Purity of isolated TANs and PBNs was evaluated by flow cytometry upon 
staining for the neutrophils/myeloid markers CD66b, CD16, myeloperoxidase (MPO), and 
CD11b. 
2.6 CRC/N co-cultures  
CRC cells from established cell lines (see above) were cultured in the presence or absence of  
neutrophils, at different ratios and tumor cell proliferation was assessed by 3H-Thymidine 
incorporation (3H-TdR). In specific experiments, induction of apoptosis in tumor cells was 
tested by annexin V/PI staining (BioLegend). 
2.7 Flow cytometry  
Cell suspensions from CRCs and tumor-free mucosa, and peripheral blood of healthy donors or 
patients with CRC, were stained with fluorochrome-conjugated antibodies specific for human 
CD66b, CD16, CD11b, (BioLegend) and CD54, CD62L, CXCR1, CXCR2 (BD Biosciences). 
Alternatively, cells were fixed and intracellular staining was performed with antibodies specific 
for MPO (28). Stained cells were analyzed by FACS Calibur flow cytometer (BD Biosciences), 
using FlowJo software (Tree Star).  
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2.8 Imagestream  
Following CD66b, CD16 and intracellular MPO-specific staining, cells were washed and re-
suspended in PBS supplemented with 0.5% FBS and 5mM EDTA, prior to processing through 
ImageStream, Mark II Imaging Flow Cytometer (Amnis, EMD Millipore). Analysis was 
performed using IDEAS software (Amnis, EMD Millipore) and neutrophils from CRC tissue, 
healthy mucosa and peripheral blood were identified based on brightfield morphology, 
granularity and CD66b expression. 
2.9 Neutrophil and CD8+ T cell co-cultures 
TANs and PBNs, obtained from HD and CRC patients were co-cultured with autologous 
peripheral blood CD8+ T lymphocytes isolated by using antibody-coated magnetic beads 
(Miltenyi Biotec) following gradient centrifugation (34). For co-stimulation experiments, 96-
well flat bottom culture plates were coated overnight with anti CD3 mitogenic mAb (TR66, a 
gift of Dr. Lanzavecchia, Bellinzona, Switzerland), or UCHT-1, (eBiosciences) at sub-optimal 
concentrations ranging between 0.5 and 5 µg/ml depending from hybridoma and lot. 
Neutrophils and CD8+ T cells, at a 0,5 106/ml concentration each were cultured in RPMI 1640 
medium supplemented with GlutaMAX I, HEPES, sodium pyruvate, non-essential amino acids, 
antibiotics (all from GIBCO) and 5% AB serum (Blood Bank, Kantonsspital Basel), thereafter 
referred to as complete medium, in the presence of anti-CD28 (1g/ml, BD Pharmingen). 
Following 24 hours incubation, expression of CD69 early T cell activation marker, was 
evaluated by flow cytometry. T cells proliferation was measured by assessing 
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) dilution in labelled CD8+ T cells 
following 72h culture by flow cytometry (34). IFN- release in culture supernatants was 
assessed by using commercial ELISA kits (BD Biosciences). When indicated, co-culture 
experiments were performed by using trans-well plates (Corning), or in the presence of anti 
CD11a (BioLegend) or control reagents. 
2.10 Immunofluorescence 
CRC sections were fixed with Formalin 4% for 15 minutes at room temperature (RT) and 
blocked with 2% goat serum diluted in PBS containing 0.3% Triton X-100 for one hour at RT. 
They were then incubated with rabbit polyclonal anti-human CD8 (Abcam) or rabbit polyclonal 
anti-human CD45RO (BiorByt) and mouse monoclonal anti-human CD66b (Biolegend) for one 
hour at 37° C. Slides were washed with PBS and incubated for one hour at RT with goat anti-
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mouse Alexa Fluor 488 and anti-rabbit 546-conjugated antibodies (Invitrogen). Nuclei were 
counterstained with 4,6-diamidino-2-phenyldole (DAPI, Invitrogen). Section were examined 
using Olympus BX61 fluorescence microscope (Olympus) and images were captured with 10x 
and 20x magnification using a F-View II camera (Olympus) and AnalySiS software (Soft 
Imaging System GmbH). 
2.11 Statistical analysis 
Statistical significance of differential expression of activation markers, cytokine release and 
cell proliferation were analyzed by Student’s T and Wilcoxon/Mann-Whitney tests, as 
appropriate. 
Associations with survival were explored using the Cox proportional hazards regression model. 
Cut-off values used to classify CRC with low or high immune cell infiltration were obtained by 
regression tree analysis (rpart package). Based on this calculation and on the test evaluability, 
threshold value for CD66b+ infiltration was set at 10 cells per punch.  After dichotomization, 
Kaplan-Meier curves were plotted, and compared by log rank test.  
Kruskal-Wallis and Jonckheere-Terpstra tests were used to determine the association of 
CD66b+ and CD8+ cell infiltration and clinical-pathological features depending on continuous 
or discrete nature of the variable. Any missing clinical-pathological information was assumed 
to be missing at random. Subsequently, CD66b+ and CD8+ cell infiltration data were entered 
into multivariate Cox regression analysis with clinical-pathological variables and hazard ratios 
(HR) and 95% confidence intervals (CI) were used to determine prognostic effects on survival 
time. Several models with additive inclusion of single clinical-pathological data were tested. 
Only age and gender of the patients did not affect the significant impact of CD66+ and CD8+ 
cell infiltration. As soon as pT or pN or any other pathological parameters were added to the 
model, CRC infiltration by CD66+ cells lost its independent prognostic value (data not shown).   
Data were analyzed using the Statistical Package Software R (Version 3.2.4, www.r-
project.org).  P-values <0.05 were considered statistically significant. 
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3. Results 
3.1 Prognostic significance of CD66b+ cell infiltration in CRC 
In previous studies we had observed that CRC infiltration by MPO+ cells is associated with 
favorable prognosis (28;35). However, this enzyme is produced by different cells of the myeloid 
lineage. Therefore, to precisely identify TANs in CRC we stained a TMA including >650 CRC 
with a mAb recognizing CD66b, a classical neutrophil marker (31). CRC infiltrating CD66b+ 
cells could be efficiently detected in punches from fixed, paraffin embedded tissues (Fig. 1A-
B). In this cohort of patients CRC infiltration by CD66b+ cells was associated with favorable 
prognosis (Fig. 1C, P: <0.001). Additional data on clinical –pathological characterists of these 
tumors are shown in table 1. 
 
 
Figure 1. CD66b+ cell infiltration in CRC is associated with favourable prognosis. CRC samples were 
stained with a CD66b specific mAb. Tumour punches are representative of low (A) and high (B) density of CRC 
infiltration by CD66b+cells. Magnification: 10×, scale bar: 100 µm. (C) Kaplan–Meier curves illustrating overall 
survival (OS) probability according to CD66b+ cell density. Numbers of deaths/total cases within each category 
are indicated.  
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3.2 Phenotypic characterization of tissue infiltrating and peripheral blood 
CD66b+ cells in patients with CRC 
Prompted by data supporting their prognostic significance, we investigated phenotypic profiles 
of neutrophils infiltrating CRC, adjacent healthy mucosa and autologous peripheral blood.  
CRC were characterized by a significantly higher infiltration by CD66b+ cells, as compared 
with autologous healthy mucosa (Fig. 2A), although wide variations were observed from patient 
to patient. Imagestream analysis indicated that tumor and mucosa associated neutrophils 
included CD66b+ cells with variable expression of MPO and CD16 (Fig. 2B).  
In order to obtain accurate quantitative data, phenotypic profiles of tissue infiltrating neutrophil 
were analyzed by flow-cytometry in comparison to PBNs. Representative examples are shown 
in figure 2C. In keeping with previous reports (35;36), we observed that sizeable percentages 
of tissue infiltrating CD66b+ neutrophils express MPO and CD16 to lower extents as compared 
to autologous PBN (Fig. 2C-D). Based on this background, and considering that MPO and 
CD16 are also expressed by cells other than neutrophils, we explored the relative prognostic 
significance of the expression of these markers in the TMA under investigation. We observed 
that CRC infiltration by CD66b+ cells is associated with improved OS also in the absence of a 
concomitantly high CD16+ or MPO+ cell infiltration (Fig. 2E-F). Furthermore, in the presence 
of a high CD66b+ cell infiltration, presence or absence of concomitant CD16+ or MPO+ high 
density infiltration did not significantly modify survival curves (P:0.75 and P:0.79, 
respectively).  
Expression of other markers was also investigated. CD66b and CD11b are similarly expressed 
in TANs and PBNs (Fig. 2C and data not shown). CD62L, CXCR1 and CXCR2 are expressed 
to lower extents in TANs, as compared to autologous PBNs (Figure 2G). This phenotypic 
profile is shared by neutrophils infiltrating adjacent autologous healthy mucosa (Figure 2D and 
G). However, higher percentages of TANs express CD54, as compared to autologous PBNs and 
mucosa infiltrating neutrophils (Fig. 2G).  
Notably, expression of all these markers is similar in PBNs from patients with CRC and HD 
(Supplementary Fig. S1).  
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Figure 2. TANs phenotype.  (A) Percentages of CD66b+ cells in CRC tissues and autologous healthy mucosa 
were determined by flow cytometry within cell suspensions following enzymatic tissue digestion. (B) 
Representative Imagestream pictures of CD66b, CD16 and MPO expression on tumour and autologous healthy 
mucosa-derived neutrophils. (C) Representative flow-cytometry plots of CD16, CD66b and MPO-specific 
stainings of autologous PBNs, healthy mucosa-derived neutrophils and TAN from a CRC patient. (D) Cumulative 
analysis of percentages of CD16 low/ high and MPO low/ high cells within gated CD66b+ cells from PB, healthy 
mucosa and tumours. (E-F) Kaplan–Meier OS curves designed according to CD66b+ high/low and CD16+ low 
(E) or CD66b+ high/low and MPO+ low (F) cell infiltration in CRC. (G) Cumulative results showing expression 
of activation markers and chemokine receptors on PBNs, healthy mucosa-derived neutrophils and TANs, as gated 
on CD66b+ cells. *= P<0.05; **= P<0.005; ***= P<0.0001.  
 
 
 
Supplementary figure 1. Phenotypic profiles of PBN from patients with CRC and HD are similar. (A) 
Representative flow-cytometry plots of CD16 and CD66b expression in PBNs from HD and patients with CRC. 
(B) Percentages of cells positive for the indicated markers in PBNs from HD and patients with CRC. (C) 
Representative pictures from ImageStream analysis of CD66b, CD16 and MPO expression in PBNs from HD and 
patients with CRC. 
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3.3 Neutrophils do not directly inhibit CRC cell proliferation 
Data from TMA analysis consistent with an anti-tumor potential of CRC infiltration by 
neutrophils prompted us to explore possible mechanisms of action. Direct effects on CRC cells 
were first considered (37). However, short life span, and relatively low numbers of cells 
recovered from clinical specimens hampered routine use of TANs in these functional assays. 
Therefore, these experiments were performed by using PBNs from patients with CRC and HD. 
Co-culture in the presence of granulocytes did not decrease proliferation (supplementary Fig. 
2A-B) nor induced apoptosis (supplementary Fig 2C) in a panel of CRC cell lines. Furthermore 
prior treatment of neutrophils with IFN-γ or N-formyl methionyl-leucyl-phenylalanine (fMLP) 
did not impact on viability and proliferation potential of co-cultured CRC cells (supplementary 
Fig. 2C). On the other hand co-culture with a CRC cell line promoted PBNs viability 
(supplementary Fig. 2D), although without modifying their phenotypic profile (supplementary 
Fig. 2E). 
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Supplementary figure 2. Co-culture with PBNs does not impact on growth of CRC cell lines.  (A) PBNs from 
healthy donors (HD) were co-cultured with 6 different CRC cell lines at a CRC: PBN ratio 1: 20, as described in 
“materials and methods”. After 72h, tumour cells proliferation was measured by 3Hthymidine incorporation. 
Similar experiment was assessed with PBNs from CRC patients as well (B). (C) Proliferative responses of LS180 
cells cultured in the absence or presence of HD PBN (N: T ratio = 1:20), with or without IFN- and fMLP as 
assessed by 3H-Thymidine incorporation after 72h. A decreased CRC proliferation was observed in the presence 
of IFN- γ and fMLP in the absence of N, the effect of these stimuli on PBN/CRC co-cultures remains unclear. (D) 
LS180 Viability was assessed by AnnexinV staining in presence of PBN from HD. (E) PBNs from HD were co-
cultured with LS180 CRC cell line at a CRC: PBN ratio 1: 20 and after 24h, PBNs viability was verified by 
Annexin V staining and the expression of their lineage and markers of activation were also measured.  
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3.4 Neutrophil/CD8+ lymphocyte cross-talk: effects on TCR triggered T cell 
activation 
Alternative mechanisms of action underlying favorable prognostic significance of TANs in 
CRC might be related to their ability to exert indirect anti-tumor effects, mediated by other cell 
subsets. CRC infiltration by CD8+ T cells has widely been reported (18) to associate with 
favorable prognosis, although their antigen specificity is largely unclear (19). Cytokines 
released by activated T cells, including GM-CSF and IFN-γ are able to activate neutrophils and 
to prolong their survival (38). More recently, neutrophils infiltrating early stage lung cancers, 
but not their peripheral blood counterpart, were shown to promote T cell response to anti CD3 
triggering (14;15).  
Initial studies suggested that CD66b+ granulocytes frequently co-localize with CD8+ and 
CD45RO+ T lymphocytes within tumor tissues (Fig. 3A-B). Based on this finding, we tested 
the ability of TANs derived from enzyme digested CRC specimens to modulate responses of 
autologous peripheral blood CD8+ T cells to anti CD3 triggering. Addition of TANs to CD8+ 
lymphocyte cultures resulted in a significantly increased expression of CD69 early activation 
marker induced by suboptimal concentrations of anti CD3 mAb in the presence of anti CD28 
mAb was observed. More importantly, IFN-γ release in these cultures was significantly 
enhanced (P: 0.01) (Fig. 3C and supplementary Fig. 3A-B). 
Consistent with data from experiments with TANs, we observed that interaction with PBNs 
from patients and HD resulted in significant increases in CD69 expression and IFN-γ release 
by autologous CD8+ lymphocytes upon stimulation with suboptimal concentrations of anti CD3 
mAb and anti CD28 mAb (Fig. 3D-E). T cells proliferation, as assessed by CFSE dilution at 72 
hours, was also significantly enhanced (Fig. 3E and supplementary Fig. 5A). In contrast, these 
co-stimulatory effects were undetectable in T cells activated with optimal mitogenic 
concentrations of anti CD3 mAb (supplementary Fig. S4A).  
Neutrophil-mediated co-stimulation critically required cell-to-cell contact since it was not 
observed in experiments performed in trans-well plates (Fig. 4A, supplementary Fig. S3B). 
Furthermore, blocking of CD11a on CD8+ T cells, preventing binding to CD54/ICAM-1 
expressed by neutrophils, significantly (P=0.015) inhibited elicitation of co-stimulatory 
functions (Fig. 4B and supplementary Fig. 3C). Notably, CD54/ICAM-1 expression appeared 
to be up-regulated in neutrophils upon culture in the presence of resting and activated CD8+ T 
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cells (Fig. 4C). Furthermore, co-culture with activated CD8+ T cells improved neutrophil 
viability (Fig. 4D).  
These data indicate that untreated granulocytes are able to co-stimulate CD8+ T cells, and that 
their effects are best detectable under sub-optimal activation conditions.  
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Figure 3. Tumour and peripheral blood-derived neutrophils enhance CD8+ T cell responsiveness. (A-B) 
Immunofluorescence staining of CD8, CD45RO and CD66b in CRC tissues. Nuclei were stained with DAPI. 
Pictures are representative of 5 different tissue specimens. Magnification 20x, scale bar: 50 µm. (C) Peripheral 
blood CD8+ T cells from patients with CRC undergoing surgical treatment were co-cultured for 24h with 
autologous, purified TAN at 1:1 ratio in the presence or absence of suboptimal concentration (1µg/ml) of anti-
CD3 (clone UCTH)  and anti CD28. CD69 expression was measured by flow-cytometry and IFN-γ release by 
ELISA. Similar experiments were performed by using PBN from patients with CRC (D) and from HD (E). In the 
latter cases, T cell proliferation and IFN-γ release were also measured upon 72h culture. 
 
 
 
 
 
 
 
Supplementary figure 3. TANs enhance CD8+ T cell responsiveness. (A) Viability showing by PI staining and 
purity of TANs obtained upon surgical specimens digestion and isolation with anti-CD66b beads. (B) 
Representative dot plots showing CD69 expression in peripheral blood CD8+ cells stimulated by suboptimal in 
the presence of anti-CD3/ anti-CD28 in presence or absence of autologous TANs. 
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Supplementary figure 4. TANs enhance CD8+ T cell responsiveness at suboptinmal concentration of anti-
CD3. (A) Cumulative flow-cytometry histograms of CD69 expression in CD8+ T cells activated by using different 
concentrations of surface bound anti-CD3 (TR66, 0.5 and 2µg/ml) and soluble anti CD28 (1µg/ml) upon overnight 
co-culture in the presence or absence of neutrophils. 
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Supplementary figure 5. CD8+/PBN cross-talk is contact dependent. (A) Representative plots displaying 
proliferation assessed by CFSE staining upon 72h culture in peripheral blood CD8+ cells stimulated by suboptimal 
concentrations of anti-CD3/ anti-CD28 in presence or absence of autologous PBN. (B) Representative dot plots 
showing CD69 expression in peripheral blood CD8+ cells stimulated by suboptimal concentrations of anti-CD3/ 
anti-CD28 in presence or absence of autologous PBN and in control and transwell conditions, preventing cell-cell 
contact. (C) Representative plots documenting the effects of anti CD11a mAb on CD69 expression in CD8+ T 
cells activated by a suboptimal concentration of anti-CD3/anti-CD28 in the presence of autologous PBNs. 
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Figure 4. Neutrophil/CD8+ T cell cross talk is mediated through CD11a/CD54 interaction. (A) Peripheral 
blood CD8+ cells were stimulated by suboptimal concentrations of anti-CD3/ anti-CD28 in presence or absence 
of autologous PBN and in conditions preventing cell contact (Transwell). (B) Cumulative data referring to the 
effects of anti CD11a mAb on the increase in CD69 expression in CD8+ T cells upon stimulation by suboptimal 
concentrations of anti-CD3/ anti-CD28 in the presence of autologous PBN. (C) CD54/ICAM-1 expression was 
tested on live PBN, following overnight co-culture in presence or absence of CD8+, in resting state or activated 
by a suboptimal concentration of anti-CD3 and anti-CD28. The panel reports a representative flow-cytometry 
histogram and cumulative data from different experiments. (D) Viability of PBN following overnight culture in 
the presence or absence of CD8+ cells in resting state or activated by a suboptimal concentration of anti-CD3 and 
anti-CD28 was assessed by annexin V/PI staining. The panel reports representative results and cumulative data 
from independent experiments. *= P<0.05. 
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3.5 Functional features of CD8+ T cells following neutrophil-mediated co-
stimulation 
Favorable prognosis in CRC has been repeatedly associated with tumor infiltration by 
“memory” T lymphocytes (18-20). To further characterize neutrophil-mediated co-stimulation 
of CD8+ T cells, we evaluated phenotypic profiles of lymphocytes activated by optimal anti-
CD3 concentrations and CD28 in the presence or absence of granulocytes for six days, e.g. 
beyond time points usually considered for detection of maximal proliferation (39).  Stimulation 
in the presence of neutrophils induced preferential expansion of CD8+ T central memory cells 
with a CD45RO+CD62L+ phenotype.  These cells were characterized by significantly lower 
expression of PD-1 exhaustion marker, as compared with those activated in the absence of 
PBNs or TANs. (Fig. 5A-B)   
Repeated TCR-mediated T cell re-stimulation may result in activation induced cell death 
(AICD) (40). This phenomenon has been extensively characterized in murine models but only 
to a lesser extent in humans. Recently however, induction of apoptosis following re-stimulation 
of human CD8+ T cells initially primed in conditions of ineffective co-stimulation has been 
successfully demonstrated (39). To address these issues in the context of neutrophil-mediated 
co-stimulation, we investigated apoptosis induction in re-stimulated CD8+ T cells initially 
primed in the presence or absence of granulocytes. Cells initially activated in the presence of 
neutrophils underwent apoptosis upon TCR triggered re-stimulation to significantly lower 
extents, as compared to T cells primed in their absence (Fig. 5C). Taken together, these results 
indicate that neutrophils enhance activation and promote survival of CD8+ T cells.  
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Figure 5. Neutrophils enhance CD8+ central memory differentiation and survival. Peripheral blood CD8+ 
cells from healthy donors were activated with optimal mitogenic concentrations of anti CD3 mAb (clone TR66, 
2µg/ml) and anti CD28 in the presence or absence of autologous PBNs for 6 days. Representative flow-cytometry 
plots and cumulative data regarding the expression of CD62L central memory marker and PD-1 exhaustion marker 
in CD45RO+ cells are reported in panels (A) and (B), respectively.  CD8+ cells untreated or initially activated by 
anti CD3/anti CD28 in the presence or absence of autologous PBNs were re-stimulated for 24h with anti CD3/anti 
CD28. Annexin/PI staining was used to evaluate percentages of CD8+ T cells undergoing apoptosis upon re-
stimulation. Representative flow-cytometry plots and cumulative data from different experiments are reported in 
panel (C). *= P<0.05. 
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3.6 Impact of TANs on the prognostic significance of CD8+ T cell infiltration 
in CRC 
“In vitro” mechanistic results urged us to analyze potential prognostic significance of combined 
CRC infiltration by neutrophils and CD8+ T cells. CRC infiltration by CD66b+ cells was 
characterized by weak, but significant, correlation with CD8+ T cell infiltration (P<0.001). 
These findings prompted us to investigate the prognostic significance of combined CRC 
infiltration by both CD66b+ neutrophils and CD8+ T cells. In our cohort (table 1), 50% of the 
tumors (325/652) were characterized by poor CD8+ and CD66b+ cell infiltration. While 39% 
(259/652) and 23% (149/652) of cases showed evidence of high CD66b+ or CD8+ T cell 
infiltration, respectively, a concomitantly high CD66b+ and CD8+ infiltrate was detectable in 
12% of CRC samples (81/652). CRC samples infiltrated by both CD66b+ and CD8+ cells 
displayed favorable prognosis whereas cancers with low CD66b+ and CD8+ cell infiltration 
were characterized by poor prognosis (Figure 6A P:<0.0001). Most interestingly, the favorable 
prognostic significance of CD8+ CRC infiltration was significantly (P: 0.011) enhanced by a 
concomitant infiltration by CD66b+ neutrophils (Fig. 6). Accordingly, CRC samples with 
concomitant high infiltration by CD66b+ and CD8+ T cells were more frequently characterized 
by pN0 stage, e.g. absence of nodal metastases (P=0.03), and a more frequent “pushing” tumor 
border (P=0.038) (table 2). Taken together, these data indicate that a cross-talk between 
neutrophils and CD8+ T cells is of clinical relevance in CRC. 
 
Figure 6. CRC infiltration by CD66b+ enhances the favourable prognostic significance of CD8+ infiltration 
in CRC. Kaplan–Meier OS curves were designed according to high and low density CD66b+ and CD8+ cell 
infiltration. *= P<0.05; **= P<0.005; ***= P<0.0005 
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Table 1. Clinical-pathological characteristics of the CRC patient cohort and their 
association with levels of CD66b+ cell infiltrate. 
 
Characteristics 
CD66 low (<10) 
 
CD66 high (>10) 
 
p-value* 
 N = 405 (50 %) N = 272 (27 %)  
Age years (mean) 69.5  69.5  0.887 
Gender 
Female 202 (50.0) 154 (56.6) 
0.126 
Male 203 (50.0) 118 (43.4) 
Tumor location 
Left-sided 
 
Right-sided 
265 
 
132 
(66.7) 
 
(33.3) 
196 
 
76 
(72.1) 
 
(27.9) 
0.214 
Histologic subtype 
Mucinous 25 (5.8) 21 (9.6) 
0.299 
Non-mucinous 380 (94.2) 270 (90.4) 
pT stage 
pT1-2 63 (15.9) 61 (22.8) 
0.027 
pT3-4 332 (84.1) 207 (77.2)  
pN stage 
pN0 189 (47.8) 161 (60.1) 
0.001 
pN1-2 206 (52.8) 107 (49.9) 
Stage 
I 42 (10.8) 51 (19.1) 
< 0.0001 
IIA 123 (31.8) 100 (37.6) 
IIBC 20 (5.2) 8 (3.5) 
IIIA/B 175 (45.2) 95 (35.7) 
IIIC 27 (7.0) 11 (4.1) 
Tumor grade 
G1-2 367 (93.1) 250 (93.3) 
0.945 
G3 27 (6.9) 18 (6.7) 
Vascular invasion 
Absent 263 (66.6) 206 (60.1) 
0.005 
Present 132 (33.4) 62 (31.9) 
Tumor border 
Pushing 106 (26.9) 94 (35.2) 
0.028 
Infiltrating 288 (73.1) 173 (74.8) 
PTL inflammation 
Absent 315 (79.7) 202 (75.4) 
0.216 
Present 80 (20.3) 66 (24.6) 
Microsatellite stability 
Deficient 48 (11.8) 35 (12.9) 
0.783 
Proficient 357 (88.2) 237 (87.1) 
5-year survival rate (95%CI) 46.7% 
(42.0-51.9) 
 
61.9% (56.3-68.0) 0.0001 
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Table 2.Clinical-pathological characteristics of the CRC patient cohort and their 
association with levels of CD8+ and CD66b+ cell infiltrate. 
Characteristics 
CD66b  low 
CD8 low 
CD66b high 
CD8 low 
CD66b low 
CD8 high 
CD66b high 
CD8 high 
 
P-
value* 
 
P-
value** 
 N =325 (50 %) N =178 (27 %) 
N = 
68 
(11 %) 
N = 
81 
(12 %)  
 
Age 
years 
(mean) 
71  70  70  69  0.480 
 
- 
 
Gender 
Female 156 (48.0) 100 (56.2) 38 (55.9) 48 (59.3) 
0.145 
 
0.74 
Male 169 (52.0) 78 (43.8) 30 (44.1) 33 (40.7)  
Tumor 
location 
Left-sided 222 (68.5) 132 (74.2) 43 (64.2) 52 (64.2) 
0.28 
 
 
1 
Right-
sided 
102 (31.5) 46 (25.8) 24 (35.8) 29 (35.8) 
 
Histologic 
subtype 
Mucinous 19 (5.8) 17 (9.6) 4 (5.9) 2 (2.5) 
0.654 
 
 
0.41 
Non-
mucinous 
306 (94.2) 161 (90.4) 64 (94.1) 79 (97.5) 
 
pT stage 
pT1-2 47 (14.8) 34 (19.2) 14 (21.5) 21 (26.8) 
0.069 
 
0.55 
pT3-4 271 (85.2) 143 (80.1) 51 (78.5) 57 (73.2)  
pN stage 
pN0 146 (46.1) 89 (50.9) 40 (60.6) 62 (77.5) 
<0.0001 
 
0.03 
pN1-2 171 (53.9) 86 (49.1) 26 (39.4) 18 (22.5)  
Tumor grade 
G1-2 300 (94.6) 170 (96.0) 58 (89.2) 67 (75.9) 
0.008 
 
0.61 
G3 17 (5.4) 7 (4.0) 7 (10.8) 11 (14.1)  
Vascular 
invasion 
Absent 210 (66.0) 132 (74.6) 45 (69.2) 64 (82.1) 
0.023 
 
0.07 
 
Present 108 (34.0) 45 (25.4) 20 (30.8) 14 (17.9) 
Tumor border 
Pushing 81 (25.6) 51 (29.0) 19 (29.2) 37 (47.4) 
0.002 
 
0.038 
 
Infiltrating 236 (74.4) 125 (71.0) 46 (70.8) 41 (52.6) 
PTL 
inflammation 
Absent 258 (81.1) 142 (80.2) 48 (73.8) 51 (65.4) 
0.017 
 
0.36 
 
Present 60 (18.9) 35 (19.2) 17 (26.2) 27 (34.6) 
Microsatellite 
stability 
Deficient 37 (15.2) 19 (14.5) 10 (16.5) 16 (32.7) 
0.166 
 
0.51 
 
Proficient 288 (84.8) 159 (85.5) 58 (83.5) 65 (67.3) 
 
 
*Clinical-pathological differences between CRC displaying CD66b+ low/CD8+ low density 
infiltration and the other three subgroups. Jonckheere test if variable numeric (age); otherwise 
Kruskal Wallis test. 
** Clinical-pathological differences between CRC displaying CD66b+ low/CD8+ high 
density or CD66b+ high/CD8+ high density infiltration. Fisher exact test. 
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4. Discussion  
Analysis of a large clinically annotated TMA including over 600 CRC reveals that CD66b+ cell 
infiltration is associated with favorable prognosis. While CRC appear to be infiltrated to a larger 
extent than autologous adjacent healthy tissue, phenotypic profiles of CRC infiltrating 
neutrophils largely match those detectable in healthy mucosa infiltrating cells. However, in 
keeping with data regarding early lung cancer infiltrating neutrophils (14;15), TAN appear to 
express CD54 to higher extents as compared to neutrophils infiltrating autologous adjacent 
healthy mucosa.   
Mechanisms potentially underlying the favorable prognostic significance of CRC infiltration 
by CD66b+ cells were investigated in detail. Our results indicate that co-culture with autologous 
neutrophils enhances TCR triggered activation of CD8+ T cells and promotes the expansion of 
a lymphocyte subset characterized by the expression of “memory” markers and a relative 
resistance to AICD induced by repeated stimulation. The relevance of these findings to CRC 
immunobiology is indirectly supported by the co-localization of neutrophils and both CD8+ 
and CD45RO+ T cells in CRC tissues. Furthermore, most importantly, CRC concomitantly 
infiltrated by neutrophils and CD8+ T cells are characterized by a significantly more favorable 
prognosis, as compared to tumors displaying high CD8+ but low CD66b+ cell infiltration. In 
contrast, high neutrophil infiltration in the absence of concomitant CD8+ lymphocytes only 
provided a modest prognostic advantage as compared to CRC where neither high CD8+ nor 
CD66b infiltrate was detectable. 
These data suggest that the favorable prognostic significance of infiltration by neutrophils in 
CRC largely relies on their interaction with CD8+ T cells, possibly based on co-stimulatory 
mechanisms, as suggested by our “in vitro” results. The potential relevance of these data might 
obviously extend beyond CRC immunobiology. These interactions might indeed be operational 
in a wider range of conditions, thus supporting the notion of a highly effective cooperation 
between innate and adaptive immune responses.  
Remarkably, similar results have also emerged from studies conducted in experimental models 
(41) and in clinical settings, including early stage lung cancer (14;15) and autoimmune and 
infectious disease. Underlying molecular mechanisms have not been fully clarified. In 
particular, cell-cell interactions mediated by OX40, CD58, CD59 and their ligands have been 
proposed (14;39). Alternatively, a role for ROS release has also been suggested (41). Our data 
suggest that CD11a/CD54 interaction powerfully contributes to the elicitation of the co-
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stimulatory effects of neutrophils on CD8+ T cell activation. Nevertheless, further research is 
warranted to obtain additional insights into underlying molecular mechanisms. 
An important limitation in studies on TANs is represented by their short life span, high 
sensitivity to enzymes necessary for the generation of single cell suspensions from clinical 
specimens and relatively low numbers, preventing the routine performance of functional 
studies. However, the consistency of data emerging by using TANs, and PBNs from patients 
with CRC and healthy donors together with the clinical data, reliably supports the concept of a 
potentially high clinical relevance of neutrophil-T cell interaction on tumor sites.  
Our study also suggests a number of additional important questions. The fact that in a variety 
of tumors other than CRC, neutrophil infiltration has been suggested to be associated with poor 
prognosis (42-44) raises the issue of the specificities inherent in neutrophil infiltration in CRC. 
Our results indicate that the favorable prognostic significance of the latter largely, albeit not 
exclusively, relies on the interaction between neutrophils and CD8+ T cells, and suggest that 
lymphocyte infiltration may represent an important pre-requisite for the detection of these 
effects. Therefore, lack of lymphocyte infiltration or infiltration by “unfavorable” T cells (45)  
might prevent a full elicitation of anti-tumor effects of neutrophils.   
Data regarding neutrophil infiltration in CRC from East Asia patients (29) appear to contradict 
our results. Genetic background may play an important role in this context. However, additional 
factors might be involved in determining the prognostic relevance of neutrophil infiltration. 
CRC oncogenesis is typically characterized by an early increase in bacterial translocation from 
the gut lumen (45) and gut microbiome composition has recently been shown to decisively 
impact on chemo- and immunotherapy outcome (46-48). Considering the key role of 
neutrophils in the response to bacteria, it is tempting to speculate that microbiome composition 
might decisively affect their ability to actively participate to anti-tumor immune response. Thus, 
differences in human gut microbiome in different geographic areas (49) might also be of 
importance in the evaluation of the prognostic significance of neutrophil infiltration in CRC. 
On the other hand, our data urge studies aimed at the clarification of mechanisms favoring the 
recruitment of granulocytes within CRC tissues. 
In conclusion, our study, providing clear evidence of the prognostic significance of concomitant 
infiltration by CD8+ cells and neutrophils in CRC, represents one of the first examples (50) of 
clinically relevant interaction between non-cancerous cells from the tumor microenvironment. 
Furthermore, it clearly identifies neutrophils as key players in CRC immunobiology. 
 76 
5. Reference  
 
 (1)  Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat 
Rev Cancer 2016;16(7):431-46. 
 (2)  Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? 
Carcinogenesis 2012;33(5):949-55. 
 (3)  Di CE, Forni G, Lollini P et al. The intriguing role of polymorphonuclear neutrophils 
in antitumor reactions. Blood 2001;97(2):339-45. 
 (4)  Templeton AJ, McNamara MG, Seruga B et al. Prognostic role of neutrophil-to-
lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer 
Inst 2014;106(6):dju124. 
 (5)  Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the 
immune system. Nat Rev Immunol 2009;9(3):162-74. 
 (6)  Guglietta S, Chiavelli A, Zagato E et al. Coagulation induced by C3aR-dependent 
NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat 
Commun 2016;7:11037. 
 (7)  Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor 
microenvironment: expect the unexpected. J Clin Invest 2015;125(9):3356-64. 
 (8)  Fridlender ZG, Sun J, Kim S et al. Polarization of tumor-associated neutrophil 
phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009;16(3):183-94. 
 (9)  Jablonska J, Leschner S, Westphal K et al. Neutrophils responsive to endogenous IFN-
beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 
2010;120(4):1151-64. 
 (10)  Granot Z, Henke E, Comen EA et al. Tumor entrained neutrophils inhibit seeding in the 
premetastatic lung. Cancer Cell 2011;20(3):300-14. 
 (11)  Finisguerra V, Di CG, Di MM et al. MET is required for the recruitment of anti-
tumoural neutrophils. Nature 2015;522(7556):349-53. 
 77 
 (12)  Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered 
to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, 
specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 
1993;90(8):3539-43. 
 (13)  Stoppacciaro A, Melani C, Parenza M et al. Regression of an established tumor 
genetically modified to release granulocyte colony-stimulating factor requires 
granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 
1993;178(1):151-61. 
 (14)  Eruslanov EB, Bhojnagarwala PS, Quatromoni JG et al. Tumor-associated neutrophils 
stimulate T cell responses in early-stage human lung cancer. J Clin Invest 
2014;124(12):5466-80. 
 (15)  Singhal S, Bhojnagarwala PS, O'Brien S et al. Origin and Role of a Subset of Tumor-
Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human 
Lung Cancer. Cancer Cell 2016. 
 (16)  Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-917. 
 (17)  Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 
2010;375(9719):1030-47. 
 (18)  Fridman WH, Pages F, Sautes-Fridman C et al. The immune contexture in human 
tumours: impact on clinical outcome. Nat Rev Cancer 2012;12(4):298-306. 
 (19)  Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells 
within human colorectal tumors predict clinical outcome. Science 
2006;313(5795):1960-4. 
 (20)  Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and 
survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66. 
 (21)  Gabitzsch ES, Tsang KY, Palena C et al. The generation and analyses of a novel 
combination of recombinant adenovirus vaccines targeting three tumor antigens as an 
immunotherapeutic. Oncotarget 2015;6(31):31344-59. 
 78 
 (22)  Mennonna D, Maccalli C, Romano MC et al. T cell neoepitope discovery in colorectal 
cancer by high throughput profiling of somatic mutations in expressed genes. Gut 2015. 
 (23)  Zlobec I, Karamitopoulou E, Terracciano L et al. TIA-1 cytotoxic granule-associated 
RNA binding protein improves the prognostic performance of CD8 in mismatch repair-
proficient colorectal cancer. PLoS One 2010;5(12):e14282. 
 (24)  Sconocchia G, Arriga R, Tornillo L et al. Melanoma cells inhibit NK cell functions. 
Cancer Res 2012;72(20):5428-9. 
 (25)  Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell 2006;124(2):263-6. 
 (26)  Nagorsen D, Voigt S, Berg E et al. Tumor-infiltrating macrophages and dendritic cells 
in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response 
against tumor-associated antigens and survival. J Transl Med 2007;5:62. 
 (27)  Sconocchia G, Zlobec I, Lugli A et al. Tumor infiltration by FcgammaRIII (CD16)+ 
myeloid cells is associated with improved survival in patients with colorectal 
carcinoma. Int J Cancer 2010. 
 (28)  Droeser RA, Hirt C, Eppenberger-Castori S et al. High myeloperoxidase positive cell 
infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS One 
2013;8(5):e64814. 
 (29)  Rao HL, Chen JW, Li M et al. Increased intratumoral neutrophil in colorectal 
carcinomas correlates closely with malignant phenotype and predicts patients' adverse 
prognosis. PLoS One 2012;7(1):e30806. 
 (30)  Yamamoto T, Kawada K, Itatani Y et al. Loss of SMAD4 Promotes Lung Metastasis of 
Colorectal Cancer by Accumulation of CCR1+ Tumor-associated Neutrophils through 
CCL15-CCR1 Axis. Clin Cancer Res 2016. 
 (31)  Galdiero MR, Bianchi P, Grizzi F et al. Occurrence and significance of tumor-
associated neutrophils in patients with colorectal cancer. Int J Cancer 2016;139(2):446-
56. 
 (32)  Amicarella F, Muraro MG, Hirt C et al. Dual role of tumour-infiltrating T helper 17 
cells in human colorectal cancer. Gut 2015. 
 79 
 (33)  Nebiker CA, Han J, Eppenberger-Castori S et al. GM-CSF Production by Tumor Cells 
Is Associated with Improved Survival in Colorectal Cancer. Clin Cancer Res 
2014;20(12):3094-106. 
 (34)  Trella E, Raafat N, Mengus C et al. CD40 ligand-expressing recombinant vaccinia virus 
promotes the generation of CD8(+) central memory T cells. Eur J Immunol 
2016;46(2):420-31. 
 (35)  Daster S, Eppenberger-Castori S, Hirt C et al. Absence of myeloperoxidase and CD8 
positive cells in colorectal cancer infiltrates identifies patients with severe prognosis. 
Oncoimmunology 2015;4(12):e1050574. 
 (36)  Hirt C, Eppenberger-Castori S, Sconocchia G et al. Colorectal carcinoma infiltration by 
myeloperoxidase-expressing neutrophil granulocytes is associated with favorable 
prognosis. Oncoimmunology 2013;2(10):e25990. 
 (37)  Ackermann MF, Lamm KR, Wiegand GW et al. Antitumor activity of murine 
neutrophils demonstrated by cytometric analysis. Cancer Res 1989;49(3):528-32. 
 (38)  Pelletier M, Micheletti A, Cassatella MA. Modulation of human neutrophil survival and 
antigen expression by activated CD4+ and CD8+ T cells. J Leukoc Biol 
2010;88(6):1163-70. 
 (39)  McKinney EF, Lee JC, Jayne DR et al. T-cell exhaustion, co-stimulation and clinical 
outcome in autoimmunity and infection. Nature 2015;523(7562):612-6. 
 (40)  Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and 
death of lymphocytes: implications for immunotherapy. Immunity 2001;14(2):105-10. 
 (41)  Schwab L, Goroncy L, Palaniyandi S et al. Neutrophil granulocytes recruited upon 
translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. 
Nat Med 2014;20(6):648-54. 
 (42)  Coffelt SB, Kersten K, Doornebal CW et al. IL-17-producing gammadelta T cells and 
neutrophils conspire to promote breast cancer metastasis. Nature 2015;522(7556):345-
8. 
 (43)  Fridlender ZG, Albelda SM, Granot Z. Promoting metastasis: neutrophils and T cells 
join forces. Cell Res 2015;25(7):765-6. 
 80 
 (44)  Liang W, Ferrara N. The Complex Role of Neutrophils in Tumor Angiogenesis and 
Metastasis. Cancer Immunol Res 2016;4(2):83-91. 
 (45)  Abreu MT, Peek RM, Jr. Gastrointestinal malignancy and the microbiome. 
Gastroenterology 2014;146(6):1534-46. 
 (46)  Iida N, Dzutsev A, Stewart CA et al. Commensal bacteria control cancer response to 
therapy by modulating the tumor microenvironment. Science 2013;342(6161):967-70. 
 (47)  Vetizou M, Pitt JM, Daillere R et al. Anticancer immunotherapy by CTLA-4 blockade 
relies on the gut microbiota. Science 2015;350(6264):1079-84. 
 (48)  Viaud S, Saccheri F, Mignot G et al. The intestinal microbiota modulates the anticancer 
immune effects of cyclophosphamide. Science 2013;342(6161):971-6. 
 (49)  Yatsunenko T, Rey FE, Manary MJ et al. Human gut microbiome viewed across age 
and geography. Nature 2012;486(7402):222-7. 
 (50)  Herrera M, Herrera A, Dominguez G et al. Cancer-associated fibroblast and M2 
macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 
2013;104(4):437-44. 
 (51)  Kostic AD, Chun E, Robertson L et al. Fusobacterium nucleatum potentiates intestinal 
tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 
2013;14(2):207-15. 
 
 
 
 
 
 
 
 
 81 
 
 
CHAPTER III: “Modulation of neutrophils 
functions by gut commensal microorganisms” 
V Governa1, 2 V Mele1, D Calabrese, H Xu1 E Trella, RA Droeser1,3, S Däster1,3, M Bolli4, L 
Terracciano2, G Iezzi1 and GC Spagnoli1,6. 
1Department of Biomedicine, Basel University Hospital and University of Basel, Basel, CH; 
2Molecular Pathology Division, Institute of Pathology, Basel University Hospital and 
University of Basel, CH; 3Department of General Surgery, Basel University Hospital and 
University of Basel, CH; 4Department of Visceral Surgery, St. Claraspital, Basel, CH; 
5Department of Visceral Surgery, Ospedale Civico, Lugano, CH.qa 
(in preparation)  
 82 
Abstract 
Purpose: Human colorectal cancer (CRC) is characterized by a peculiar microenvironment 
including a large number of microorganisms. Among them, F.nucleatum has been associated 
with CRC progression, triggering tumorigenesis and resulting in severe prognosis. Immune 
cells also have a fundamental role on CRC development. While immune system, tumor cells 
and bacteria are key components of the “ménage à trois” of the CRC microenvironment, many 
aspects of their interactions remain to be investigated. Here, we analyzed the effects of 
F.nucleatum on phenotypes and functional features of CD66b+ neutrophils.  
Experimental design: CD66b+ cell infiltration and presence of F,nucleatum within CRC 
tissues (>50 evaluable CRC samples) and corresponding healthy mucosa was assessed by RT-
PCR. Phenotypes and cytokine release profiles of peripheral blood CD66b+ cells cultured in 
the presence of F.nucleatum were evaluated by flow cytometry and Luminex assays, 
respectively. Moreover CD66b+/ CD8+ and CD66b+/Tumor associated stromal cells crosstalk 
was investigated through in vitro experiments in presence of F.nucleatum and B.fragilis.  
Results: We report that the infiltration by CD66b+ cells in CRC significantly correlates with 
the presence of F.nucleatum. In vitro experiments using CRC lines revealed a high secretion of 
IL-8 induced by F.nucleatum, resulting in an increase of neutrophil recruitment. Functional 
studies indicate that neutrophils cultured in the presence of F.nucleatum are devoid of direct 
antitumor potential and their viability, phenotype and cytokine release potential is dramatically 
affected as compared with cultures performed in the presence of control gram- bacteria. 
Moreover, in presence of F.nucleatum CD66b+ cells lose their capability to stimulate CD8+ 
cells. Importantly, Neutrophils affected by F.nucleatum -and not by B.fragilis- induce a high 
release of IL-6 by tumor associated stromal cells, potentially leading enhanced tumor cell 
proliferation. 
Conclusions: F.nucleatum may impair the ability of neutrophils to elicit anti-tumor functions 
within the CRC microenvironment. 
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1. Introduction 
Neutrophils represent the predominant immune cell type in human peripheral blood and play a 
major role in the first line immune response against infectious microorganisms. However, their 
role in anti-tumor responses in humans has not been investigated in detail. In previous studies 
we have characterized tumor associated neutrophils (TANs) infiltrating human colorectal 
cancer (CRC) and we have shown that they are able to enhance the responsiveness of autologous 
CD8+ T cells to TCR triggering. Most importantly, we have also shown that infiltration by 
neutrophils enhances the prognostic significance of CRC infiltration by CD8+ T cells, thus 
suggesting that they might effectively promote antitumor immunity (Governa et al., in press).  
 A major peculiarity of CRC microenvironment, is represented by the interplay between gut 
microbiota and tumor cells as recently reported (1). Indeed tumor progression has been shown 
to be dependent on both innate and adaptive immune system activation and on quality and 
quantity of intestinal microflora. Alterations of host-microbiome interaction, frequently 
referred to as “dysbiosis”, have been suggested to significantly contribute to CRC development 
(2). However, underlying mechanisms are still largely unclear.  
Multistep CRC development is accompanied by the expression of Apc, K-Ras and p53 
mutations and by morphological alterations, leading to early increase of mucosal permeability 
and the activation of the mucosal and systemic immune system. Numerous studies have 
compared microbial community composition in CRC and in normal mucosa and in patients and 
healthy subjects. In particular, Fusobacterium nucleatum has been shown to be most 
reproducibly associated with CRC (3;4). 
Remarkably, F.nucleatuam has been shown to modulate immune responses as well. In a mouse 
model, this bacterium favored CRC progression by releasing short-peptides and short-chain of 
fatty acids into the tumour microenvironment, serving as chemo-attractants for myeloid- 
derived suppressors cells (MDSCs). Furthermore, Kostic et al observed increased infiltration 
of TAMs, TANs, and DCs, in colonic-adenomas of F.nucleatum –infected mice, as compared 
with controls. 
High density T cell infiltration has been associated with favorable prognosis in CRC (5;6). 
Recently, extent of F.nucleatum colonization in various CRC patients has been shown to be 
inversely correlated with CD3+ T cell infiltration (CD8+, CD4+, CD45RO+, FOXP3+ cells) 
thus suggesting that it might downregulate T cell-mediated antitumour immune responses 
thereby promoting colorectal tumour progression (7-9). 
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Based on this background, in this study we explored the potential role of F.nucleatum on 
Neutrophils within the CRC context. To this purpose we have analyzed the correlation between 
F.nucleatum colonization and neutrophil infiltration in CRC microenvironment. Furthermore 
we have investigated the impact of F.nucleatum on neutrophil functions and how this 
interaction could affect the interplay with other components of the CRC microenvironment, 
including CD8+ lymphocytes and Tumor associate stromal cells (TASC). 
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2. Materials and methods 
2.1 Tumor cell lines - Clinical specimen collection - Neutrophil and 
lymphocyte isolation  
Please refer to methods described in Chapter II. 
2.2 Bacteria  
Fusobacterium nucleatum (subsp. Nucleatum, ATCC 25586), Bacteroides vulgatus (Eggerth 
and Gagnon, ATCC 8482), and Bacteroides fragilis (non enterotoxigenic strain 9343, ATCC 
25285), were kindly provided by Dr. Nina Khanna, Department of Biomedicine, University of 
Basel. They were cultured under anaerobic conditions.  
2.3 Real-time reverse transcription PCR assays  
Total RNA was extracted from stored CRC tissues or sorted cell populations using Trizol 
(Invitrogen) and reverse transcribed using the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT, Invitrogen) and Random Primers. Quantitative Real-Time PCR 
was performed in the ABI prism™ 7700 sequence detection system, using Syber green (Roche) 
and TaqMan Universal Master Mix and No AmpErase UNG (both from Applied Biosystems).  
F.nucleatum primers by Microsyth:  
FW- GCCTCACAGCTAGGGACAAC 
RW- GAGTAAGGGCCGTGTCTCAG 
2.4 CRC/PBN/Bacteria co-cultures  
Cells from established cell lines were cultured in the presence or absence of  neutrophils (PBN: 
LS180 = 20:1) and bacteria, at different ratios and tumor cell proliferation was assessed by 3H-
Thymidine incorporation (3H-TdR) upon 72h culture.  
2.5 Flow cytometry  
Cell suspensions from CRCs and tumor-free mucosa, and peripheral blood of healthy donors or 
patients with CRC, were stained with fluorochrome-conjugated antibodies specific for human 
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CD66b, CD16, CD11b, (BioLegend) and CD62L, (BD Biosciences). Alternatively, cells were 
fixed and permeabilized, and intracellular staining was performed by using antibodies specific 
for MPO (10). Stained cells were analyzed by FACS Calibur flow cytometer (BD Biosciences), 
using FlowJo software (Tree Star).  
2.6 PBN and CD8+ T cell co-cultures 
TANs and PBNs, obtained from HD and patients with CRC were co-cultured with autologous 
peripheral blood CD8+ T lymphocytes isolated by using antibody-coated magnetic beads 
(Miltenyi Biotec) following gradient centrifugation (11). For co-stimulation experiments, 96-
well flat bottom culture plates were coated overnight with anti CD3 mitogenic mAb UCHT-1, 
(eBiosciences) at sub-optimal concentrations ranging between 0.5 and 5 µg/ml depending from 
hybridoma and lot. Neutrophils and CD8+ T cells, at a 0,5 106/ml concentration each were 
cultured in RPMI 1640 medium supplemented with GlutaMAX I, HEPES, sodium pyruvate, 
non-essential amino acids, antibiotics (all from GIBCO) and 5% AB serum (Blood Bank, 
Kantonsspital Basel), thereafter referred to as complete medium, in the presence of anti-CD28 
(1g/ml, BD Pharmingen). T cell proliferation was measured by assessing carboxyfluorescein 
succinimidyl ester (CFSE, Invitrogen) dilution in labelled CD8+ T cells following 72h culture 
by flow cytometry (11). IFN- release in culture supernatants was assessed by using commercial 
ELISA kits (BD Biosciences). Neutrophils were purified as detailed above and re-suspended in 
complete medium. They were then treated for 1 hour with Fusobacterium nucleatum and 
Bacteroides Fragilis heat-killed and opsonized with 10% HS for 15’. Following washing, 
neutrophils were added to CD8+ cells culture. 
2.7 PBN response to bacteria 
Phenotypic profiles of bacteria-treated neutrophils (ratio PBN : bacteria = 1:5) were analyzed 
by flow cytometry at defined time points between 2 and 24 hours, with particular attention to 
surface markers typically modulated in inflammatory states, such as CD16, CD66b, CD11b and 
CD62L. In parallel experiments, bacteria-treated neutrophils were co-cultured in complete 
medium with autologous CD8+ T cells in flat bottom 96 well plates previously sensitized with 
anti CD3 mAbs at sub-optimal concentrations (see above). Expression of CD69 activation 
marker, expression of IFN-γ gene and cytokine release and T cell proliferation were evaluated 
as detailed above.  In specific experiments, induction of apoptosis in PBN by Bacteria was 
tested by Annexin V/PI staining (BioLegend). Supernatant of PBNs cultured with bacteria were 
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collected upon overnight stimulation and used for Luminex Multiplex assay (Invitrogen, 
Thermo Fisher Scientific). 
2.8 Tumor associated stromal cells (TASC) isolation 
Tumor-associated stromal cells were isolated from freshly excised CRC samples, obtained from 
consenting patients undergoing surgical treatment. The tissue sample was rinsed with PBS 
(GIBCO) and minced using scissors or scalpels. It was then transferred to digestion medium 
containing serum-free DMEM (GIBCO), supplemented with Collagenase IV (100x; 20kU/ml; 
Worthington #CLSS-4), DNAse I (100x; 50 mg/ml; Sigma-Aldrich #D5025), HEPES (10mM; 
GIBCO #15630-056), Kanamycin (100x; GIBCO #15160-047), Amphotericin B (100x; 
250ug/mL; Sigma-Aldrich #A9528), Metronidazol (250x; 200mg/ml, Braun), Cefuroxim 
(250x; 15mg/ml, Braun). 
The suspensions were shaken vigorously for few seconds and then digested for 1 hour at 37°C 
on continuous smooth rotation. After digestion, the suspensions were filtered through a 100μm 
(Falcon #352360) and then 70μm (Falcon #352350) nylon mesh Cell Strainer. Cell in 
suspensions were counted and used for other purposes, while the small chunks remaining on 
the top of the 100µm filter were picked up with tweezers and transferred into wells of a 12-well 
plates (about 3 per well). Two milliliters of alpha MEM supplemented with 10% Fetal Bovine 
serum (GIBCO), Kanamycin (100x; GIBCO #15160-047), GlutaMAX-I (10mM) Sodium 
Pyruvate (100mM) were added in each well. Cells were cultured at 37°C with 5% CO2. The 
medium was changed twice per week and the cell outgrowth was monitored by light 
microscopy.  
After an initial isolation period, TASCs were expanded in vitro, characterized by flow 
cytometry for the purity of the population by using CD90 antibody, and, if necessary, sorted by 
flow cytometry. 
2.9 TASC and CRC cell lines co-culture 
LS180 CRC cells line was co-cultured with TASC at different ratios, for 5 days in tumor cell 
medium. In specific experiments, supernatants collected from PBNs cultured with bacteria 
overnight, from 4 different HD donors were filtered and added to cultures every 24h for 5 days. 
Monocultures of TASC or tumor cells were used as controls. At the end of culture periods, 
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supernatants were collected and IL-6 release was evaluated by ELISA (Biolegend). 
Additionally, cells were harvested and used for subsequent FACS and gene expression analyses. 
2.10 Migration Assay 
PBNs suspended in serum-free medium were seeded into upper chambers of transwell plates 
onto uncoated or matrigel-coated membranes (4 µm pore size, BD Biosciences). Lower 
chambers contained medium collected upon co-culture of LS180 CRC cell line and 
F.nucleatum (Fn) or B.fragilis (Bf). Plates were incubated at 37°C. After 20 hours inserts were 
removed and the numbers of PBNs that had migrated into the lower chambers were quantified 
by CyQUANT Cell Proliferation Assay Kit (Invitrogen, Carlsbad, CA). 
2.11 Measurement of ROS  
PBNs from healthy donors are resuspended in HBSS medium and concentrated at a 2x106 /ml 
concentration. The different concentrations of F.nucleatum pre-incubated with HS 5% for 15’ 
RT were directly and rapidly added at the MicroLumat plus (Berchtold Technologies). The 
indirect amount of produced HOCl (ROS) by oxidant Luminol has been detected in 25 cycles 
at interval with 5 minutes, for a total of 120 minutes with a constant temperature of 37°. 
Negative controls were stimuli-free samples. 
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3. RESULTS 
3.1 F.nucleatum in CRC patients. 
We first addressed the presence of F.nucleatum (Fn) in tissues from a limited cohort of CRC 
patients (n=30). Evidence of the presence of Fn colonization in a sizeable percentage of cases 
in our tumor cohort could be reliably obtained by RT-PCR. Importantly in 70% of cases, 16s 
Fn expression was significantly higher in tumor tissues as compared to autologous healthy 
mucosa (Figure 1).  
Figure 1. F.nucleatum in CRC patients cohort. Colorectal cancer tissue and the corresponding healthy mucosa 
was collected upon surgery operation and preserved in RNA later. Upon RNA extraction by Trizol the same 
quantity of RNA was retro-transcripted. 16S of Fn was detected by RT-PCR on 62 samples. Additionally a 
standard curve was performed using RNA of different quantity of F.nucleatum. The amount of  Fn is here 
evaluated  as Ct. 
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3.2 Correlation between neutrophil infiltration and F.nucleatum colonization 
in CRC. 
In initial studies we comparatively investigated F.nucleatum colonization and neutrophil 
infiltration in healthy mucosa and CRC tissues. We identified 30 CRC samples out of 54 
showing evidence of sizeable F.nucleatum colonization, as quantified by PCR assays assessing 
16S expression. Remarkably, a highly significant correlation (r=0.6077) was observed between 
extent of F.nucleatum colonization and CD66b gene expression tumor (Fig 2A). Although 16S 
F.nucleatum was represented to higher extents in tumor tissues, as compared to corresponding 
healthy mucosa, a positive correlation was also observed in normal tissues (Fig 2B). 
A 
 
B 
  
Figure 2. F.nucleatum/ CD66b correlation ex vivo. Colorectal cancer tissue and the corresponding healthy 
mucosa was collected upon surgery operation and preserved in RNA later. Upon RNA extraction by Trizol the 
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same quantity of RNA was retro-transcripted. 16S of Fn was detected by RT-PCR on 62 samples. Additionally a 
standard curve was performed using RNA of different quantity of F.nucleatum. After quantification of Fn 
detectable on the different CRC samples and corresponding mucosa, the samples with quantifiable amount of 16S 
Fn were normalized on GAPDH and correlated to the gene expression of CD66b+ cells displayed into 
corresponding samples. 
3.3 F.nucleatum impacts neutrophils phenotype and functionality 
It is now well recognized that the CRC microenvironment critically impacts on clinical 
outcome. My previous results identified tumor infiltration granulocytes as positive prognostic 
marker in CRC and neutrophils as active partners of adaptive T cell responses. Additionally, 
we found that CRC-infiltrating neutrophils are a heterogeneous population of cells differentially 
expressing CD66b, CD16, CD62L, CD54 and MPO. Thus, we hypothesized that heterogeneity 
of TANs in CRC, as compared to PBNs, and their differential density as compared to 
autologous healthy mucosa, may depend on the composition and the inherent complexity of the 
tumour microenvironment.  
Based on this background, we investigated how components of CRC-microenvironment, such 
as cytokines released by other CRC-infiltrating immune cells and specific microbiota strains 
could contribute to TAN phenotypic heterogeneity and density within tumor tissue. 
First, we observed that IFN and GM-CSF, whose expression in CRC tissues is associated with 
favorable prognosis enhance PBN survival “in vitro” and induce upregulation of important 
adhesion molecules such as CD11b and CD54/ICAM-1 on PBN surface  (Figure 3A-B).  
Interestingly, as mentioned before, very recent observations have documented that gut 
microbiome may be profoundly altered in CRC patients. In particular, the Gram-negative strain 
F.nucleatum is known to preferentially colonize human CRC (3) and to induce gut 
tumorigenesis and Granulocyte recruitment in vivo (12). 
PBNs stimulated with heat-inactivated F. nucleatum (Fn) showed a rapid decrease in  CD16 
expression and reduced viability (Figure 4 A-C-D), accompanied by an increased expression of 
CD66b, CD11b, CD54 and a down-regulation of CD62L and intracellular MPO expression 
(Figure 4E). On the other hand, PBNs stimulation with a different gram–negative strain, such 
as Bacteroides fragilis (Bf) that also colonize CRC, did not appear to induce a similar 
phenotypic profile. 
Based on the differential phenotype displayed by PPBNs in presence of F.nucleatum we then 
hypothesized that F.nucleatum could also affect PBNs functions. Therefore we collected 
supernatants of PBNs stimulated with Fn and Bf upon overnight incubation and we assessed 
cytokine and chemokine release in these conditions (Figure 5A). 
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PBNs stimulated by FN show an increased IL8 release as compared to controls and Bf 
stimulated PBN. Interestingly F.nucleatum had the capability to trigger CCL2 and IL1Ra 
release by PBNs. These factors are known to be endowed with pro-inflammatory and immune 
suppressive potential and may induce tumourigenesis (13;14). Our results show that 
F.nucleatum is able to confer to PBNs a distinct functional profile that may impair the functions 
of other cells of the tumor microenvironment. 
 
Taken together these results suggest that cytokines associated to prolonged CRC survival, 
namely IFN- and/or GM-CSF, could account for the accumulation of live CD16+/MPO+ in 
CRC tissues. However we have observed that pre-incubation of purified neutrophils with 
F.nucleatum modulates their phenotypes in a manner closely reminding phenotypic profiles 
frequently observed in CRC or mucosa infiltrating neutrophils. Moreover PBNs stimulated by 
F.nucleatum are characterized by a pro-tumoural factor release profile. 
Thus, local cytokine production and bacterial colonization may modulate phenotype and 
functions of TANs thereby differentially impacting on tumor microenvironment. 
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Figure 3. Cytokine-activated PBN. (A) PBNs were cultured in presence of IFNγ  (1ng/ml) and GM-CSF (1ng/ml) 
and upon 24h culture PBNs phenotype was assessed by FACS analysis. Representative plot shows that IFNγ 
promotes PBN survival, as evaluated by Annexin V staining. Furthermore CD16 expression is maintained and 
increased CD54, CD11b, CD64 and HLA-DR expression is also observed (B). 
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Figure 4. Modulation of markers’ expression in PBNs by bacterial stimuli. (A-C) PBNs from HD were 
cultured in the presence or absence of bacteria (ratio 1:5) and viability and phenotypic profiles were assessed after 
2h. (Representative plot displays a significant reduction of CD16 expression in presence of Fn but not of Bf. (B) 
PBNs viability was impaired as well upon stimulation with Fn. (D) Representative pictures from ImageStream 
analysis of CD66b, CD16 and MPO expression in PBNs in presence of Fn. (E) CD54 and CD11b and CD66b 
upregulation is observed upon stimulation with Fn and, to a lower extent, in presence of Bf. In contrast CD62L 
and intracellular MPO expression are reduced upon co-culture with Fn.  
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Figure 5. Cytokine release profile of PBNs upon stimulation with bacteria. Peripheral blood neutrophils from 
four different healthy donors were cultured for 2 hours in the presence or absence of the indicated bacterial stimuli. 
Supernatants were then collected and the release of the indicated factors was assessed by Luminex technology. 
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3.4 Direct effects of F.nucleatum on CRC cell lines proliferation and PBNs 
migration. 
Colorectal colonization by the Gram-negative microbiota F.nucleatum has been associated with 
CRC outgrowth in vivo and CRC cell proliferation in vitro. In our hands, we could not observe 
any increase of CRC cell lines proliferation in presence of different concentrations of 
F.nucleatum (Figure 6A). However, we observed an enhancement of IL8 production by LS180 
cell line in presence of F.nucleatum resulting in increased PBNs migration as compared to 
control and Bf stimulated tumor cells (Figure 6 B-C).  
                                                                                                       IL-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Direct effect of F.nucleatum on CRC cell lines. (A) Proliferative responses of LS180 cells cultured in 
the presence or absence of  F. nucleatum (Fn) at different ratios (1:1000,1:500,1:250) as assessed by 3H-Thymidine 
incorporation after 72h. (B) Supernatant of LS180 treated with Fn or B.fragilis (Bf) was collected following 
overnight incubation and IL-8 release was measured by ELISA assay. (C) Migration assay using transwell plates 
was performed to investigate neutrophil migration in basal condition or following stimulation by different bacterial 
strains. 
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3.5 Neutrophils and F.nucleatum cross-talk does not influence CRC cell 
growth 
We were intrigued by the negative effect of F.nucleatum on PBN survival. We hypothesized 
that PBNs could act as “scavengers” of CRC-associated bacteria and therefore directly impact 
on tumor cells killing by release of cytotoxic compounds. Indeed PBNs in presence of 
F.nucleatum display a major production of ROS, MPO, and TRAIL, (Figure 7A-B-C). 
Therefore we investigated whether cytotoxic effects of PBNs on CRC tumor growth could be 
detectable upon F.nucleatum stimulation.  
 However, although stimulated PBNs release high amounts of MPO/ROS, they fail to display 
cytotoxic activity towards CRC cells (Figure. 7D). Indeed our results shown that PBNs are 
unable to kill tumor cells upon stimulation with F.nucleatum and other microrganisms (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Release of cytotoxic effector factors induced by Fn on PBNs does not impair CRC lines 
proliferation. (A) ROS production by Neutrophils in the presence or absence of F. nucleatum. (B-C) Supernatant 
from LS180 cells cultured overnight in the presence or absence of Fn and Bf was collected and MPO and TRAIL 
release was measured by ELISA assays. (D) Proliferative responses of LS180 cells cultured in the absence or 
presence of neutrophils (PBN: LS180 ratio = 1:5) and F.nucleatum, as assessed by 3H-Thymidine incorporation 
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after 72h culture. Neutrophils activated by F. nucleatum do not impact on CRC cells proliferation (unpaired t-test; 
p > 0.05). 
3.6 F.nucleatum abolishes the PBNs stimulatory effects on CD8 
Our previous experiments (see chapter II) clearly indicate that granulocytes mediate co-
stimulation of adaptive T cell responses independently of their putative antigen presentation 
potential.  
To further characterize neutrophil-mediated co-stimulation of CD8+ T cells, we investigated 
whether the priming of PBNs with the different, previously described, bacteria may lead to 
divergent immunomodulation. Our data indicate that pre-incubation with Fn, but not with Bf, 
fully abolishes their co-stimulatory potential, as measured by CD69+ expression (data not 
shown), proliferation (Figure 8A-B) and IFN-γ release. 
The response of CD8+ cells to PBN might be abolished primarily due to the low viability of 
PBNs cultured in the presence of F.nucleatum. However, a role of the production of 
immunosuppressive factors, including IL1Ra, induced by F.nucleatum on PBNs, should not be 
disregarded.  
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Figure 8. (A-B) Peripheral blood CD8+ T cells were co-cultured for 72h with purified PBNs at 1:1 ratio in the 
presence or absence of suboptimal concentration (1µg/ml) of anti-CD3 (clone UCTH) and anti CD28. PBNs were 
previously treated for 1 hour with heat-killed F.nucleatum (Fn) or Bacteroides Fragilis (Bf). Following washing 
PBNs were then added to CD8+ cells cultures. The supportive role of neutrophils on CD8+ T cell proliferation 
induced by anti CD3/CD28 was abolished following treatment with F.nucleatum as showed by CFSE assays. 
Representative flow-cytometry plots and cumulative data from different experiments are reported. 
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3.7 Indirect effects of PBN on tumor growth. 
We then considered the possibility that PBNs activated by F.nucleatum could modulate CRC 
growth by conditioning the functions of tumor associated stromal cell (TASC), which have been 
shown to play crucial roles on CRC progression (15). Our data suggest that co-culture of CRC 
and TASC in the presence of supernatants of PBN activated by F. nucleatum (sFn) results in 
enhanced tumour cell proliferation and IL-6 release likely by TASC (Figure 9A-D). A similar 
experiment performed in presence of supernatants of PBN activated by B.fragilis (sBf) did not 
provide any evidence of pro-tumorigenic effects (Figure 9B). 
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Figure 9. sPBNs enhance IL6 release by TASC upon culture with F.nucleatum. LS180 CRC cell line, was 
cultured alone (TC) or with TACS (TC+TASC) at ratio of 1:1 for 5 days and with supernatants previously collected 
from PBN alone (sPBN) or cultured with F.nucleatum (sPBN+Fn) or B.fragilis (sPBN Bf). The different 
supernatants were collected and filtered were added every 24h. The co-cultured cells and the controls were then 
harvested to assess cell numbers and FACS analysis to normalize EpCAM and CD90 expression. (A) TASC induce 
an increased proliferation of CRC cells. (B) Supernatants of the different conditions were tested for IL6 by ELISA 
assay. Data (mean ± SD) from three independent experiments are shown. (C) Expression levels of IL-6 genes were 
evaluated by quantitative PCR, using GAPDH as reference gene. (D) IL6 release by TASC without TC was also 
tested. 
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4. Discussion 
Our work demonstrates that bacteria present in CRC microenvironment and potentially 
associated to tumor progression may impact on phenotype and functions of Neutrophils in vitro. 
Considering the important findings by other groups on the relevance of F.nucleatum 
colonization in CRC, we focused on this bacterial strain. 
Our results show that F.nucleatum colonization of CRC or healthy mucosa is significantly 
correlated with density of infiltrating neutrophils. However, our “in vitro” data indicate that 
PBN rapidly undergo apoptosis in the presence of F.nucleatum, whereas these effects are 
delayed, in the presence of other gram–negative bacteria, such as B.fragilis. Importantly, PBNs 
cultured in presence of F.nucleatum appear to express CD66b and CD11b to higher extents than 
controls and PBNs stimulated by other gram–negative bacteria. In contrast, expression of CD16 
and MPO is rapidly down regulated in PBNs cultured with F.nucleatum.  
On the other hand, interestingly, in the presence of F.nucleatum CRC cell lines produce high 
amounts of IL-8, potentially able to recruit neutrophils to tumor tissues.  PBNs released high 
amounts of MPO, ROS CCL2, CCL4, IL1Ra and IL8 upon stimulation by F.nucleatum. 
However, these activities did not promote the cytotoxic potential of neutrophils against tumor 
cells, but were rather associated with immunosuppressive effects since PBNs cultured in the 
presence of F.nucleatum failed to co-stimulate CD8+ cells activated by TCR triggering.  
Taken together, these data lead us to hypothesize a scenario where tumor cells in presence of 
F.nucleatum recruit neutrophils into tumor niche as a “cell trap” where these cells are induced 
to undergo apoptosis and the elicitation of their CD8+ T cell co-stimulation potential is 
prevented, as also suggested by mouse models. High F.nucleatum loads may then impact on 
the functionality of a variety of immune cell players. Previous work, for instance, has shown 
that F.nucleatum high colonization is inversely associated with the density of CRC infiltrating 
CD3+ cells, although not significantly associated with CD8+ lymphocyte density.  
Interestingly, we also observed that supernatants from F.nucleatum stimulated PBN enhance 
the release of IL6 by tumor associated stromal cells (TASC), which might, in turn, promote 
tumor proliferation. Still unclear however, is the nature of the neutrophil-derived soluble factors 
involved in the elicitation of these effects.  
Additional studies are warranted to investigate the effects induced on neutrophils by other 
components of the gut microbiome. Nevertheless, our data suggest, that bacteria may 
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differentially attract neutrophils to the tumor niche, and modulate their phenotype and immune 
functions.  
Taken together, our results contribute to the characterization of complex interactions taking 
place in CRC microenvironment elucidating the relationship occurring between microbiota and 
neutrophils, key components of innate immune system. Our findings further underline the 
potential relevance of the interaction between microbiota and immune cells as target for CRC 
prevention and treatment. 
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CHAPTER IV:  discussion and outlook 
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1. Discussion  
Neutrophils play an indispensable and established  role in defense against microorganisms 
infection, however new appreciation for their significance in cancer immunobiology has started 
to emerge (16). 
During the last decade important studies has shown the profound influence of these dynamic 
cells throughout each step of carcinogenesis. In fact in mice models it has been demonstrated 
that neutrophils are able to acquire distinct phenotypes and even opposing functions by 
polarizing into N1 and N2 cells in analogy with the well described M1 and M2 polarized 
macrophage states. The molecular mechanisms underlying neutrophil polarization are not 
clearly defined. Cytokines present within the tumor microenvironment could drive this 
polarization process although N2 cells appear to display immature neutrophils characteristics. 
Therefore whether N2 are activated or immature neutrophils remain to be elucidated. 
Furthermore in most of the experimental models studied, neutrophils appear to elicit pro-
tumorigenic and even immunosuppressive functions.  
The role of neutrophils in humans concerns still needs to be investigated. Neutrophil infiltration 
in cancers is frequently considered as a negative prognostic factor but the biological 
mechanisms underlying their clinical relevance are unclear. 
Colorectal cancer microenvironment critically affects disease progression and is characterized 
by peculiar features. In particular, tumor infiltration by memory CD8+ T cells has repeatedly 
been reported to be associated with favorable prognosis. Furthermore, defined commensal 
bacterial strains, preferentially found to be associated with CRC, have been suggested to favor 
tumor progression (17). Taken together these data indicate that the interaction between 
cancerous cells, immune system and commensal microorganisms may play a key role in the 
control of tumor progression and impact CRC clinical course. 
Original reports from our group and data presented in my thesis do indicate that, at difference 
with cancers from different histological and anatomical origin, CRC infiltration by myeloid 
cells is also associated with favorable prognosis. During the first phase of our study we have 
explored “in vitro” mechanisms potentially underlying the “in vivo” favorable prognosis. First, 
we hypothesized a direct tumor killing by neutrophils. Despite activation by a variety of stimuli, 
in our hands neutrophils were unable to exert cytotoxic or cytostatic effects on established CRC 
cell lines. Indeed high MPO/ROS production induced by neutrophil activation did not suffice 
to induce tumor cells death or to arrest their proliferation.  
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Most interestingly, we have observed that granulocyte infiltration appears to significantly 
enhance the favorable prognostic significance of CD8+ T cell infiltration in CRC. These 
findings pose the question of the analysis of the granulocyte/CD8+ T cell cross-talk potentially 
taking place in CRC tissues and of the ability of different bacterial strains to condition it. 
While activated T cells are known to release cytokines promoting neutrophils survival and 
activation, the ability of neutrophils to support TCR triggered T cell activation is debated. Our 
data do indicate that, in the presence of neutrophils, anti-CD3 stimulated CD8+ T cells are 
characterized by higher expression of activation markers, and higher proliferation and IFN-γ 
release. This co-stimulatory effect induced by PBN on CD8+ cells is cell-to-cell contact 
dependent. CD11a (LFA-1) on CD8+ and CD54 (ICAM1) on Neutrophils, are the molecules 
involved in this interaction, although a role of other co-stimulatory molecules such OX40L, or 
4-BBL cannot be excluded. These findings might shed some light on the favorable prognostic 
significance of CRC infiltration by both CD8+ T cells and granulocytes. Importantly, these 
effects are only visible upon sub-optimal T cell activation, but become undetectable when 
optimal concentrations of mitogenic anti-CD3 mAbs are used. In the latter conditions however, 
whereas neutrophils do not enhance CD8+ T cell proliferation, they induce a preferential 
expansion of CD8+ central memory T cells, showing a decreased expression of PD-1 
“exhaustion” marker. CRC infiltration by cells displaying this phenotypic profile is indeed 
known to be associated with favorable prognosis.  
A major peculiarity of CRC microenvironment is represented by its close interaction with large 
numbers of microorganisms. Therefore, we considered the hypothesis that defined bacterial 
species may influence neutrophil functions and, as a consequence, their interplay with tumor 
cells and CD8+ cells.  
Within this frame, we have shown that F.nucleatum specifically impacts on PBN phenotype 
and viability. Indeed, the expression of CD66b and CD16, main phenotypic markers of 
neutrophils, are modulated by F.nucleatum. Moreover F.nucleatum dramatically reduces PBN 
life span. F.nucleatum was able to induce in neutrophils a major production of ROS and MPO 
and the release of CCL2, CCL4, IL1Ra and IL8. These activities did not promote the cytotoxic 
potential of neutrophils against tumor cells, but could rather be of immunosuppressive 
significance.  
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Additionally we have observed that PBN stimulated supernatants collected by with 
F.nucleatum enhance the release of IL6 by tumor associated stromal cells (TASC) that may 
trigger tumor proliferation. 
I am aware of the fact that my work suffers from a number of limitations inherent in the short 
life span of granulocytes and difficulties associated with assays with tissue-derived cells, 
usually available in small numbers, and barely amenable to standard assessments. Furthermore, 
experimental models frequently fail to provide reliable support to these studies due to major 
differences between human and murine granulocyte compartments. 
Nevertheless, my experimental findings, especially if considered in combination with clinical 
data, strongly suggest that the interaction between neutrophils and CD8+ T cells may be 
endowed with major anti-tumour significance.  Although we did not observe any direct killing 
of tumor cells induced by neutrophils we could speculate that they might indirectly, but 
effectively, promote anti-tumour CD8+ cell functions. Furthermore, I could document the 
inhibitory effects of F.nucleatum on neutrophil co-stimulatory functions and survival, possibly 
resulting in the enhancement of tumor cell proliferation mediated by TASC activation. 
Taken together, my results urge an integrated analysis of human tumor microenvironment 
taking into account its different components and the specificities inherent in anatomic location 
and histological origin of different cancer types. Moreover, they further underline the critical 
relevance of the interactions between non-transformed cells and commensal flora, potentially 
impacting clinical course of malignant diseases and patient survival. 
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2. Outlook 
Our data do suggest a number of additional studies of clinical, translational and basic 
immunology relevance. 
First, they help defining immune infiltrate features directly associated with disease prognosis. 
Thus, the inclusion of neutrophil infiltration in the analysis of CRC immune contexture could 
be of relevance in clinical decision making, recommending the use of adjuvant treatments in 
patients bearing poorly infiltrated CRC following “curative” surgery or less aggressive surgical 
approaches in cancers where biopsies could provide evidence of high immune cell infiltration. 
It is tempting to speculate that these measures might have a major impact on quality of life and, 
ultimately, on patient survival.   
Second, our initial data show that microbiome composition might condition the composition of 
the immune cell infiltrate in CRC. Treatments aimed at modifying gut microbiome, promoting 
colonization with strains associated with CRC infiltration by prognostically significant immune 
cells while decreasing colonization by “unfavorable” strains could be envisaged. Our findings 
may provide an interesting experimental set up for a preliminary analysis of potentially relevant 
features of defined microorganisms. 
Third, the effects of Fn on neutrophil phenotypes, viability and functions urges a detailed 
analysis of underlying molecular mechanisms. Their significance might extend beyond the 
CRC immunobiology and apply to other areas, including infectious and autoimmune diseases 
and IBD. 
Last but not least, our results contribute to the overall clarification of the co-stimulatory 
significance of granulocyte interaction with T cells. These studies suffer from the poor viability 
of human neutrophils “in vitro” and by a relative scarcity of experimental models, considering 
the poor matching of human and murine neutrophil features “in vivo”. However, this research 
area appears to be highly promising and might contribute to the definition of a better integrated 
vision of the interaction between innate and adaptive immune systems.    
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 The study by Doester et al. identifies myeloperoxidase (MPO+) as an independent positive 
prognostic marker in CRC patients. We also proved by flow cytometry and 
immunofluorescence that not all MPO+ cells are CD66b positive. This implies that MPO+ cells 
include other immune population as macrophages, thus indicating that MPO cannot be 
considered as a reliable marker to identify neutrophils. Based on that, we investigated whether 
the CD66b marker -uniquely express on neutrophils-, could be associated with a differential 
prognostic significance as compared to MPO, in particular when analyzed in combination with 
CD8+ cell infiltration. 
In my work presented in chapter II (Governa et al., under revision), I observed that CD66b+ 
cell infiltration represents a positive prognostic factor in CRC similarly to MPO+ cell 
infiltration, with a higher p-value (0.0001 versus 0.038). Most importantly, we could identified 
a synergistic effect on the overall survival rate based on CRC infiltration by both CD8+ and 
CD66b+ cells that, in contrast, was not detectable with MPO+ and CD8+ cells.  
My contribution to this study consisted in the identification of the MPO+ CD66b- subset. I 
subsequently proposed and developed the idea to further investigate CD66b+ cells infiltration, 
which later became the main aim of my PhD project.  
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The study published by Amicarella et al. shows that Th17 cell infiltration in CRC is correlated 
with MPO+ and CD16+ cell infiltration. Moreover, in vitro data have demonstrated that in 
addition to IL-17, Th17+ cells release a spectrum of chemokines and cytokines, including IL-
8, capable to promote the recruitment of neutrophils. Th17+ cells did not significantly impact 
on CRC prognosis when detected in the stroma. However, we could show that intratumoral 
Th17+ cell infiltration is associated with a favorable prognosis. Considering that CRC 
infiltration by Th17+ cells was correlated with CD8+ and MPO+ cell cell infiltration, we could 
speculate that the positive prognostic significance of intratumoral Th17 + cells is might be due 
to their role in the recruitment of other cell subsets associated with positive prognosis, including 
CD8+, MPO+ and CD16+ cells. 
This has prompted me to investigate the functional role of neutrophil infiltration into CRC.  
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Biology of Human Tumors
The Interplay Between Neutrophils and
CD8þ T Cells Improves Survival in Human
Colorectal Cancer
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Abstract
Purpose: Tumor inﬁltration by different T lymphocyte subsets
is known to be associated with favorable prognosis in colorectal
cancer. Still debated is the role of innate immune system. We
investigated clinical relevance, phenotypes, and functional fea-
tures of colorectal cancer–inﬁltrating CD66bþ neutrophils and
their crosstalk with CD8þ T cells.
Experimental Design: CD66bþ and CD8þ cell inﬁltration was
analyzed by IHC on a tissue microarray including >650 evaluable
colorectal cancer samples. Phenotypic proﬁles of tissue-inﬁltrat-
ing and peripheral blood CD66bþ cells were evaluated by
ﬂow cytometry. CD66bþ/CD8þ cells crosstalk was investigated
by in vitro experiments.
Results: CD66bþ cell inﬁltration in colorectal cancer is signif-
icantly associated with increased survival. Interestingly, neutro-
phils frequently colocalize with CD8þ T cells in colorectal cancer.
Functional studies indicate that although neutrophils are devoid
of direct antitumor potential, coculture with peripheral blood or
tumor-associated neutrophils (TAN) enhances CD8þ T-cell acti-
vation, proliferation, and cytokine release induced by suboptimal
concentrations of anti-CD3 mAb. Moreover, under optimal acti-
vation conditions, CD8þ cell stimulation in the presence of
CD66bþ cells results in increasing numbers of cells expressing
CD45RO/CD62L "central memory" phenotype. Importantly,
combined tumor inﬁltration by CD66bþ and CD8þ T lympho-
cytes is associatedwith signiﬁcantly better prognosis, as compared
with CD8þ T-cell inﬁltration alone.
Conclusions: Neutrophils enhance the responsiveness of
CD8þ T cells to T-cell receptor triggering. Accordingly, inﬁl-
tration by neutrophils enhances the prognostic signiﬁcance
of colorectal cancer inﬁltration by CD8þ T cells, suggesting
that they might effectively promote antitumor immunity.
Clin Cancer Res; 23(14); 3847–58. 2017 AACR.
Introduction
Granulocytes account for 50%–70% of leukocytes in humans.
They represent a ﬁrst-line defense against bacterial and fungal
infections (1, 2). However, clinical and prognostic relevance of
granulocyte inﬁltration in human cancers is debated (1–3). A
number of studies suggest that high granulocyte/lymphocyte
ratios in peripheral blood are associated with poor prognosis in
different malignancies (4). Furthermore, myeloid cells of the
granulocytic lineage at different maturation stages were shown
to represent sizeable subsets of myeloid-derived suppressor cells
(MDSC), promoting tumor growth and inhibiting cancer-speciﬁc
adaptive responses (5).
More recently, the possibility that neutrophils might promote
antitumor immune responses of clinical relevance has started to
be explored (2). In particular, the ability of neutrophils to polarize
intoN1 andN2 functional proﬁles, similarly tomacrophages, has
been documented in experimental models (6, 7). Furthermore,
tumor "educated" neutrophils were shown to elicit antimetastatic
effects (8), and interaction of hepatocyte growth factor (HGF)
with its receptor MET was suggested to play a key role in the
recruitment of neutrophils mediating antitumor activities (9).
Earlier studies indicated that production by tumor cells of G-CSF
or granulocyte-macrophage colony-stimulating factor (GM-CSF),
promoting neutrophil survival and activation, could induce adap-
tive antitumor immune responses and regression of established
tumors based on neutrophil–T-cell interaction (10, 11). Further-
more, the ability of early-stage lung cancer–inﬁltrating neutro-
phils to support T-cell proliferation and antitumor responses has
been demonstrated (12, 13). However, their prognostic signiﬁ-
cance was not addressed.
Colorectal cancer represents the third cause of cancer-related
mortality worldwide. Tumor–node–metastasis (TNM) staging,
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routinely used to identify patients eligible for different treatments
is frequently ineffective in predicting colorectal cancer clinical
course (14).
Clinical relevance of the composition of tumor inﬁltrate in
colorectal cancer has been extensively investigated. Colorectal
cancer inﬁltration by CD8þ and memory T cells has been con-
sistently associated with favorable prognosis (15, 16). The spec-
iﬁcity of these cells is largely unclear. Recognition of differenti-
ation antigens or neoantigens (17) expressed by tumor cells was
reported. Alternatively, bystander effects related to T-cell
responses against antigens frommicrobial commensal could also
be hypothesized. Interestingly, expression of activation markers
by colorectal cancer–inﬁltrating lymphocytes correlates with pro-
longed survival (18).
The role of the innate immune system is unclear. NK-cell
inﬁltration is modest and apparently devoid of prognostic sig-
niﬁcance (19). Although tumor inﬁltration by myeloid cells is
associated with poor prognosis in a variety of cancers (20),
macrophage inﬁltration has been suggested to correlate with
favorable prognosis in colorectal cancer (21).
The role of neutrophils has not been comparably explored. We
previously observed that colorectal cancer inﬁltration by CD16þ
myeloid cells correlates with favorable outcome (22). Similarly to
neutrophils, these cells are HLA-class II and largely myeloperox-
idase (MPO)þ (23). Data from other groups suggest that high
tumor inﬁltration by CD66bþ neutrophils may correlate with
either benign or poor prognosis in patients with colorectal cancer.
In a cohort of East Asianpatients (n¼229), neutrophil inﬁltration
was associated with severe prognosis (24). Moreover, neutrophil
inﬁltration in colorectal cancer–derived lung metastases has
been suggested to be associated with severe prognosis following
surgical excision (25). However, neutrophil inﬁltration in colo-
rectal cancer was reported to be associated with responsiveness
to 5-ﬂuorouracil (5-FU) treatment (26). Thus, clinical signiﬁ-
cance of tumor-associated neutrophils (TAN)-inﬁltrating colo-
rectal cancer is still unclear and underlying functional mechan-
isms remain to be elucidated.
We have analyzed the prognostic signiﬁcance of colorectal
cancer–inﬁltrating CD66bþ neutrophils by using a clinically
annotated tissue microarray (TMA) including >650 cases. In
addition, we have comparatively evaluated the phenotypes of
neutrophils fromhealthy and cancerous colon tissues and periph-
eral blood frompatients andhealthy donors (HD). Their ability to
support adaptive immune responses was speciﬁcally addressed.
Finally, the prognostic relevance of the association of neutrophils
withCD8þ T cells inﬁltrating colorectal cancermicroenvironment
was explored.
Materials and Methods
TMA construction
The TMA used in this work was constructed using >650 non-
consecutive, formalin-ﬁxed, and parafﬁn-embedded primary
colorectal cancer samples, from the tissue BioBank of the Institute
of Pathology of the University Hospital Basel (Switzerland;
refs. 18, 22). A semiautomated tissue arrayer was used to transfer
punches of a 0.6-mm diameter from tissue blocks onto glass
slides. Punches derived from tumor centers and consisted of at
least 50% tumor cells. Clinical–pathologic data for patients
included in the TMA are summarized in Supplementary Tables
S1 and S2. Use of clinical information was approved by the local
ethical authorities.
IHC
TMA slides were incubated with primary antibodies speciﬁc for
CD8, CD16, MPO (18, 22, 23), and CD66b (clone G10F5,
Biolegend). Secondary staining and negative controls were per-
formed as described previously (18, 22, 23). Colorectal cancer
inﬁltration by cells expressing deﬁned markers was scored by
experienced pathologists.
Tumor cell lines
Established human colorectal cancer cell lines (DLD1,
HCT116, SW480, HT29, and SW620) were purchased from
European Collection of Authenticated Cell Cultures (ECACC).
DLD1 and HCT116 were cultured in RPMI1640 supplemented
with 10% FBS, GlutaMAX-I, nonessential amino acids (NEAA),
100 mmol/L sodium pyruvate, 10 mmol/L HEPES (all from
Gibco). HT29 cells were cultured in McCoy 5A medium (Sigma-
Aldrich), supplemented with 10% FBS, GlutaMAX-I, and kana-
mycin (Gibco). SW480 and SW620 cells were cultured in
L15 medium (Sigma-Aldrich), supplemented with 10% FBS,
GlutaMAX-I, and kanamycin (Gibco). Absence of mycoplasma
contamination was veriﬁed by PCR, prior to experimental
procedures.
Clinical specimen collection and processing
Clinical specimens from consenting patients undergoing sur-
gical treatment at Basel University Hospital St. Claraspital, Basel,
Switzerland, and Ospedale Civico (Lugano, Switzerland), were
obtained according to procedures approved by local ethical
commissions. Tumor tissues and corresponding tumor-free
mucosa fragments were embedded in optimal cutting tempe-
rature compound for further histologic evaluation or enzymati-
cally digested by using an enzyme cocktail including 200 U/mL
collagenase IV (Worthington Biochemical Corporation) and
0.2 mg/mL DNAse I (Sigma-Aldrich for 1 hour at 37C) to obtain
single-cell suspensions, as described previously (27).
Translational Relevance
Composition of tumor microenvironment impacts on can-
cer progression and clinical course. Regarding colorectal can-
cer, inﬁltration by CD8þ T lymphocytes is associated with
improved survival, but the role of myeloid cells is unclear. We
have observed that colorectal cancer inﬁltration by CD66bþ
neutrophils is associated with favorable prognosis. We
hypothesized that their prognostic signiﬁcance may be related
to their ability to support CD8þ T-cell responses. Indeed, we
found that colorectal cancer–derived tumor associated and
peripheral blood neutrophils from patients with colorectal
cancer andhealthy donors enhanceCD8þ lymphocyte respon-
siveness to T-cell receptor (TCR) complex triggering. Most
importantly, the prognostic signiﬁcance of CD8þ T-cell inﬁl-
tration in colorectal cancer is signiﬁcantly improved by a
concomitant neutrophil inﬁltration. These data powerfully
support the use of a reﬁned analysis of colorectal cancer
immune contexture for clinical decision making and identify
neutrophils as important players in antitumor immune
responses in colorectal cancer.
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Neutrophil and lymphocyte isolation
TANs were isolated from tumor cell suspensions by positive
selection of CD66bþ cells with antibody-coated microbeads
according to the manufacturer's instructions (Miltenyi Biotec,
code: 130-104-913). Heparinized peripheral blood was collected
from patients with colorectal cancer prior to surgery or fromHDs,
and density-gradient centrifugation was performed. Sedimented
fractions containing high-density neutrophils were washed and
treated with dextran 4% (T500, Pharmacia) in saline solution and
residual erythrocytes in supernatants were lysed by using lysis
buffer (Miltenyi Biotec). Peripheral blood neutrophils (PBN)
were further enriched by positively removing contaminating cells,
using the EasySep Human Neutrophil Enrichment Kit (StemCell
Technologies). Purity of isolated PBN and TAN was evaluated by
ﬂow cytometry upon staining for the neutrophils/myeloid mar-
kers CD66b, CD16, myeloperoxidase (MPO), and CD11b and
exceeded 98% and 80%, respectively, in cells used in functional
assays. Average percentages of apoptotic cells in PBN and TAN
suspensions used in functional assays, as measured by Annexin
V/PI staining (BioLegend), did not exceed 5% and 20%, respec-
tively. Peripheral blood and tumor-inﬁltrating CD8þ lympho-
cytes (TIL)were isolated fromperipheral bloodmononuclear cells
(PBMC) obtained by gradient centrifugation or digested tumor
specimens, respectively, by using anti CD8-coatedmagnetic beads
(Miltenyi Biotec), as described previously (28).
Colorectal cancer/neutrophil cocultures
Colorectal cancer cells from established cell lines were cul-
tured in the presence or absence of neutrophils untreated or
previously treated for 1 hour with IFNg or fMLP (Sigma) at
different ratios and tumor cell proliferation was assessed by 3H-
Thymidine incorporation (3H-TdR). In speciﬁc experiments,
induction of apoptosis in tumor cells was tested by Annexin
V/PI staining.
Flow cytometry
Cell suspensions from colorectal cancers and tumor-freemuco-
sa, andperipheral bloodofHDsor patientswith colorectal cancer,
were stained with ﬂuorochrome-conjugated antibodies speciﬁc
for human CD66b, CD16, CD11b (BioLegend) and CD54,
CXCR1, CXCR2 (BD Biosciences). Alternatively, cells were ﬁxed
and intracellular staining was performed with antibodies speciﬁc
for MPO (23). Stained cells were analyzed by FACSCalibur ﬂow
cytometer (BD Biosciences), using FlowJo software (Tree Star).
Imagestream
Following CD66b, CD16, and intracellular MPO-speciﬁc
staining, cells were washed and resuspended in PBS supple-
mented with 0.5% FBS and 5mmol/L EDTA, prior to processing
through ImageStream, Mark II Imaging Flow Cytometer
(Amnis, EMD Millipore). Analysis was performed using IDEAS
software (Amnis, EMD Millipore) and neutrophils from colo-
rectal cancer tissue, healthy mucosa, and peripheral blood were
identiﬁed on the basis of brightﬁeld morphology, granularity,
and CD66b expression.
Neutrophil and CD8þ T-cell cocultures
PBNs and TANs, obtained from HD and colorectal cancer
patients, were cocultured with CD8þ T cells from autologous
peripheral blood or tumor specimens. For costimulation experi-
ments, 96-well ﬂat-bottom culture plates were coated overnight
with anti-CD3 mitogenic mAb (TR66, a gift of Dr. Lanzavecchia,
Bellinzona, Switzerland), or UCHT-1 (eBiosciences), at subopti-
mal concentrations ranging between 0.5 and 5 mg/mL depending
from hybridoma and lot. Neutrophils and CD8þ T cells at a 0.5
106/mL concentration each were cultured in RPMI1640 medium
supplemented with GlutaMAX I, HEPES, sodium pyruvate, non-
essential amino acids, antibiotics (all from Gibco), and 5% AB
serum (Blood Bank, Kantonsspital, Basel, Switzerland), thereafter
referred to as complete medium, in the presence of anti-CD28 (1
mg/mL, BD Pharmingen). After 24-hour incubation, expression of
CD69 early T-cell activation marker was evaluated by ﬂow cyto-
metry. T-cell proliferation was measured by assessing carboxy-
ﬂuorescein succinimidyl ester (CFSE, Invitrogen) dilution in
labeled CD8þ T cells following 72-hour culture by ﬂow cytometry
(28). IFNg release in culture supernatants was assessed by using
commercial ELISA Kits (BD Biosciences). When indicated, cocul-
ture experimentswere performedbyusing Transwell plates (Corn-
ing), or in the presence of anti-CD11a (BioLegend) or control
reagents.
Immunoﬂuorescence
Colorectal cancer sections were ﬁxed with formalin 4% for 15
minutes at room temperature and blocked with 2% goat serum
diluted in PBS containing 0.3% Triton X-100 for 1 hour at room
temperature. They were then incubated with rabbit polyclonal
anti human CD8 (Abcam) or rabbit polyclonal anti human
CD45RO (BiorByt) and mouse monoclonal anti human CD66b
(Biolegend) for 1 hour at 37C. Slides were washed with PBS and
incubated for 1 hour at room temperature with goat anti-mouse
Alexa Fluor 488 and anti-rabbit 546–conjugated antibodies (Invi-
trogen). Nuclei were counterstained with 4,6-diamidino-2-phe-
nyldole (DAPI, Invitrogen). Sections were examined using Olym-
pus BX61 ﬂuorescence microscope (Olympus) and images were
captured with 10 and 20 magniﬁcation using an F-View II
camera (Olympus) and AnalySiS software (Soft Imaging System
GmbH).
Statistical analysis
Statistical signiﬁcance of differential expression of activa-
tion markers, cytokine release, and cell proliferation was
analyzed by Student t and Wilcoxon/Mann–Whitney tests,
as appropriate.
Associations with survival were explored using the Cox pro-
portional hazards regressionmodel. Cut-off values used to classify
colorectal cancer with low or high immune cell inﬁltration were
obtained by regression tree analysis (rpart package). On the basis
of this calculation and on the test evaluability, threshold value for
CD66bþ inﬁltration was set at 10 cells per punch. After dichot-
omization, Kaplan–Meier curves were plotted, and compared by
log-rank test.
Kruskal–Wallis and Jonckheere–Terpstra tests were used to
determine the association of CD66bþ and CD8þ cell inﬁltra-
tion and clinical–pathologic features depending on continu-
ous or discrete nature of the variable. Any missing clinical–
pathologic information was assumed to be missing at random.
Subsequently, CD66bþ and CD8þ cell inﬁltration data were
entered into multivariate Cox regression analysis with clinical–
pathologic variables and HRs and 95% conﬁdence intervals
(CI) were used to determine prognostic effects on survival
time.
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Data were analyzed using the Statistical Package Software R
(Version 3.2.4, www.r-project.org). P values <0.05 were consid-
ered statistically signiﬁcant.
Ethical commission approval
Ethikkommission Nordwest- und Zentralschweiz (EKNZ), no.
2014-388.
Results
Prognostic signiﬁcance of CD66bþ cell inﬁltration in colorectal
cancer
In previous studies, we had observed that colorectal cancer
inﬁltration by MPOþ cells is associated with favorable prog-
nosis (23). However, this enzyme is produced by different cells
of the myeloid lineage. Therefore, to precisely identify TANs in
colorectal cancer, we stained a TMA including >650 colorectal
cancer with a mAb recognizing CD66b, a classical neutrophil
marker (26). Colorectal cancer–inﬁltrating CD66bþ cells could
be efﬁciently detected in punches from ﬁxed, parafﬁn-embed-
ded tissues (Fig. 1A and B). In this cohort of patients, high
colorectal cancer inﬁltration by CD66bþ cells, as dichotomized
by using a cut-off value (n ¼ 10) obtained by regression tree
analysis (see "Materials and Methods"), was associated with
increased overall survival (OS; Fig. 1C, P ¼ 0.0001). Similar
results were observed when CD66bþ cell inﬁltration was ana-
lyzed by dichotomizing data using median (n ¼ 5) or mean
(n ¼ 16.5) values as cutoff (P ¼ 0.0003 and 0.001, respectively)
or by using nondichotomized continuous log 10–transformed
CD66bþ cell inﬁltration values (P < 0.0001). Interestingly,
high-density CD66bþ cell inﬁltration was signiﬁcantly associ-
ated with pT1–2 stage (P ¼ 0.027), pN0 stage (P ¼ 0.001),
clinical stage (P < 0.0001), absence of vascular invasion (P ¼
0.005), and "pushing" (18) tumor borders (P ¼ 0.028; Sup-
plementary Table S1).
Phenotypic characterization of tissue-inﬁltrating and
peripheral blood CD66bþ cells in patients with colorectal
cancer
Prompted by data supporting their prognostic signiﬁcance, we
investigated phenotypic proﬁles of neutrophils inﬁltrating colo-
rectal cancer, adjacent healthymucosa, and autologous peripheral
blood.
Colorectal cancer were characterized by a signiﬁcantly (P ¼
0.0009) higher inﬁltration by CD66bþ cells, as compared with
autologous healthy mucosa (Fig. 2A), although wide variations
were observed from patient to patient. Imagestream analysis
indicated that TAN and mucosa-associated neutrophils included
Figure 1.
CD66bþ cell inﬁltration in colorectal
cancer is associated with favorable
prognosis. Colorectal cancer
samples were stained with a CD66b
speciﬁc mAb. Tumor punches are
representative of low (A) and high (B)
density of colorectal cancer inﬁltration
by CD66bþ cells. Magniﬁcation: 10,
scale bar, 100 mm. C, Kaplan–Meier
curves illustrating overall survival (OS)
probability according to CD66bþ cell
density. Numbers of deaths/total
cases within each category are
indicated.
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Figure 2.
TANs phenotype. A, Percentages of CD66bþ cells in colorectal cancer tissues and autologous healthy mucosa were determined by ﬂow cytometry within cell
suspensions following enzymatic tissue digestion. B, Representative imagestream pictures of CD66b, CD16, and MPO expression on tumor and autologous healthy
mucosa-derived neutrophils. C, Representative ﬂow cytometry plots of CD16, CD66b, and MPO-speciﬁc staining of autologous PBNs, healthy mucosa–derived
neutrophils and TAN from a colorectal cancer patient. D, Cumulative analysis of percentages of CD16 low/high and MPO low/high cells within gated CD66bþ cells
from PB, healthymucosa, and tumors. E and F, Kaplan–Meier OS curves designed according to CD66bþ high/low and CD16þ low (E) or CD66bþ high/low and MPOþ
low (F) cell inﬁltration in colorectal cancer. G, Cumulative results showing expression of CD54 and chemokine receptors on PBNs, healthy mucosa-derived
neutrophils and TANs, as gated on CD66bþ cells.  , P < 0.05;  , P < 0.005;  , P < 0.0001.
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CD66bþ cells with variable expression of MPO and CD16
(Fig. 2B).
To obtain accurate quantitative data, phenotypic proﬁles
of tissue-inﬁltrating neutrophil were analyzed by ﬂow cytome-
try in comparison to PBNs. Representative examples are
shown in Fig. 2C. In keeping with previous reports (22, 23),
we observed that sizeable percentages of tissue-inﬁltrating
CD66bþ neutrophils express MPO and CD16 to lower extents
as compared with autologous PBN (Fig. 2C and D). On the
basis of this background, and considering that MPO and CD16
are also expressed by cells other than neutrophils, we explored
the relative prognostic signiﬁcance of the expression of these
markers in the TMA under investigation. We observed that
colorectal cancer inﬁltration by CD66bþ cells is associated with
improved OS also in the absence of a concomitantly high
CD16þ or MPOþ cell inﬁltration (Fig. 2E and F). Furthermore,
in the presence of a high CD66bþ cell inﬁltration, presence or
absence of concomitant CD16þ or MPOþ high-density inﬁl-
tration did not signiﬁcantly modify survival curves (P ¼ 0.75
and 0.79, respectively).
Expression of other markers was also investigated. CD66b
and CD11b are expressed in similarly high percentages of TANs
and PBNs (data not shown), whereas CXCR1 and CXCR2 are
expressed to lower extents in TANs, as compared with autol-
ogous PBNs (Fig. 2G). This phenotypic proﬁle is shared by
neutrophils inﬁltrating adjacent autologous healthy mucosa
(Fig. 2D and G). However, higher percentages of TANs express
CD54, as compared with autologous PBNs and mucosa-inﬁl-
trating neutrophils (Fig. 2G).
Notably, phenotypic proﬁles of PBNs from patients with colo-
rectal cancer and HD are similar (Supplementary Fig. S1).
Neutrophils do not directly inhibit colorectal cancer cell
proliferation
Data from TMA analysis consistent with an antitumor poten-
tial of colorectal cancer inﬁltration by neutrophils prompted us
to explore possible mechanisms of action. Direct effects on
colorectal cancer cells were ﬁrst considered (29). However,
short life span, and relatively low numbers of cells recovered
from clinical specimens hampered routine use of TANs in these
functional assays. Therefore, these experiments were per-
formed by using PBNs from patients with colorectal cancer
and HDs. Coculture in the presence of granulocytes did not
decrease proliferation (Supplementary Fig. S2A and S2B) nor
induced apoptosis (data not shown) in a panel of colorectal
cancer cell lines. Prior treatment of neutrophils with IFNg or
fMLP also failed to impact on viability and proliferation
potential of cocultured colorectal cancer cells (Supplementary
Fig. S2C).
Neutrophil/CD8þ lymphocyte cross-talk: effects on TCR–
triggered T-cell activation
Alternative mechanisms of action underlying favorable prog-
nostic signiﬁcance of TANs in colorectal cancermight be related to
their ability to exert indirect antitumor effects, mediated by other
cell subsets. Colorectal cancer inﬁltration by CD8þ T cells has
widely been reported to associate with favorable prognosis (15),
although their antigen speciﬁcity is largely unclear. Cytokines
released by activated T cells, including GM-CSF and IFNg , are able
to activate neutrophils and to prolong their survival (30). More
recently, neutrophils inﬁltrating early-stage lung cancers, but not
their peripheral blood counterpart, were shown to promote T-cell
response to anti-CD3 triggering (12, 13).
Initial studies suggested that CD66bþ granulocytes frequently
colocalize with CD8þ and CD45ROþ T lymphocytes within
tumor tissues (Fig. 3A and B). On the basis of these ﬁndings, we
tested the ability of TANs derived from enzyme-digested colorec-
tal cancer specimens tomodulate responses of autologous periph-
eral blood CD8þ T cells to anti-CD3 triggering. Upon addition of
TANs to CD8þ lymphocyte cultures, a signiﬁcantly (P ¼ 0.006)
increased expression of CD69 early activation marker induced by
suboptimal concentrations of anti-CD3 mAb in the presence of
anti CD28 mAb was observed. Furthermore, importantly, IFNg
release in these cultures was also signiﬁcantly enhanced (P ¼
0.01; Fig. 3C). Consistent with data from experiments with TANs,
we observed that interaction with PBNs from patients (Fig. 3D)
and HD (Fig. 3E) resulted in signiﬁcant increases in CD69
expression and IFNg release by autologous CD8þ lymphocytes
upon stimulation with suboptimal concentrations of anti-CD3
mAb and anti-CD28 mAb. Representative ﬂow cytometry plots
are reported in Supplementary Fig. S3B and cumulative data are
reported in Fig. 3D and E. T-cell proliferation, as assessed by CFSE
dilution at 72 hours, was also signiﬁcantly enhanced. Represen-
tative ﬂow cytometry proﬁles are shown in Supplementary Fig.
S3D, whereas cumulative data are reported in Fig. 3E. In contrast,
these costimulatory effects were undetectable in T cells activated
with optimal mitogenic concentrations of anti-CD3 mAb (Sup-
plementary Fig. S3A).
Neutrophil-mediated costimulation critically required cell-to-
cell contact as it was not observed in experiments performed in
Transwell plates (Fig. 4A; Supplementary Fig. S3B). Furthermore,
blocking of CD11a onCD8þ T cells, preventing binding to CD54/
ICAM-1 expressed by neutrophils, signiﬁcantly (P ¼ 0.015)
inhibited elicitation of costimulatory functions (Fig. 4B; Supple-
mentary Fig. S3C). Notably, CD54/ICAM-1 expression appeared
to be upregulated in neutrophils upon culture in the presence of
resting and activated CD8þ T cells (Fig. 4C). Furthermore, cocul-
ture with activated CD8þ T cells improved neutrophil viability
(Fig. 4D).
These data indicate that untreated TAN and PBN are able to
costimulate CD8þ T cells, and that these effects are detectable in
suboptimal activation conditions.
Neutrophil-mediated costimulation results in increased
memory CD8þ T-cell numbers
Favorable prognosis in colorectal cancer has been repeatedly
associated with tumor inﬁltration by "memory" T lymphocytes
(15, 16). To further characterize neutrophil-mediated costimula-
tion of CD8þ T cells, we evaluated phenotypic proﬁles of lym-
phocytes activated by optimal anti-CD3 concentrations and
CD28 in the presence or absence of granulocytes for 5 days,
thus, beyond time points usually considered for detection of
maximal proliferation (31). Remarkably, peripheral blood CD8þ
T-cell stimulation in the presence of PBN resulted in signiﬁcantly
increased percentages of "central" memory cells expressing a
CD45ROþ/CD62Lþ phenotype. Representative examples and
cumulative data are reported in Fig. 5A. However, in the presence
of TAN, these effects were only detectable in four of seven
experiments performed with cells from different patients (data
not shown).
Similar experiments were also performed by using TAN and
autologous tumor-derived CD8þ TIL. These cells are characterized
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by phenotypic proﬁles different from autologous peripheral
blood CD8þ T cells. In particular, signiﬁcantly higher percentages
of CD8þ TIL, as compared with peripheral blood CD8þ T cells, do
expressCD69 (71.9%19.1%vs. 1.6% 0.6%,n¼4,P¼0.008)
or CD45RO (64.5%  25.7% vs. 22.5  10%, n ¼ 4, P ¼ 0.02),
consistent with a locally "activated" state. However, we observed
that the percentage of CD62Lþ cells was markedly increased in
anti-CD3/CD28–stimulated cultures performed in the presence
of autologous TAN, as compared with cultures performed in
their absence, in CD8þ TILs derived from three out of four
tumors tested, whereas it was identical in a fourth. Accordingly,
IFNg release upon anti CD3/CD28 stimulation in cultures of
CD8þ TIL from two out of three different tumor specimens
tested was higher in the presence than in the absence of
autologous TAN. Representative data and cumulative results
are shown in Fig. 5B and C.
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Tumor and peripheral blood–derived
neutrophils enhance CD8þ T-cell
responsiveness. A and B,
Immunoﬂuorescence staining of CD8,
CD45RO, and CD66b in colorectal
cancer tissues. Nuclei were stained
with DAPI. Pictures are representative
of ﬁve different tissue specimens.
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C, Peripheral blood CD8þ T cells from
patients with colorectal cancer
undergoing surgical treatment were
cocultured for 24 hours with
autologous, puriﬁed TAN at 1:1 ratio in
the presence or absence of suboptimal
concentration (1 mg/mL) of anti-CD3
(clone UCTH) and anti-CD28. CD69
expression was measured by ﬂow
cytometry and IFNg release by ELISA.
Similar experiments were performed
by using PBN from patients with
colorectal cancer (D) and from HD (E).
In the latter cases, T-cell proliferation
and IFNg release were also measured
upon 72-hour culture.
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Impact of TANs on the prognostic signiﬁcance of CD8þ T-cell
inﬁltration in colorectal cancer
"In vitro" mechanistic results urged us to analyze potential
prognostic signiﬁcance of combined colorectal cancer inﬁltra-
tion by neutrophils and CD8þ T cells. Colorectal cancer inﬁl-
tration by CD66bþ cells was characterized by weak, but sig-
niﬁcant, correlation with CD8þ T-cell inﬁltration (P < 0.001).
These ﬁndings prompted us to investigate the prognostic sig-
niﬁcance of combined colorectal cancer inﬁltration by both
CD66bþ neutrophils and CD8þ T cells. In our cohort (Supple-
mentary Table S2), 50% of the tumors (325/652) were char-
acterized by poor CD8þ and CD66bþ cell inﬁltration. Although
39% (259/652) and 23% (149/652) of cases showed evidence
of high CD66bþ or CD8þ T-cell inﬁltration, respectively, a
concomitantly high CD66bþ and CD8þ inﬁltrate was detect-
able in 12% of colorectal cancer samples (81/652). Colorectal
cancer samples inﬁltrated by both CD66bþ and CD8þ cells
displayed favorable prognosis, whereas cancers with low
CD66bþ and CD8þ cell inﬁltration were characterized by poor
prognosis (Fig. 6A, P < 0.0001). Most interestingly, the favor-
able prognostic signiﬁcance of CD8þ colorectal cancer inﬁltra-
tion was signiﬁcantly (P ¼ 0.011) enhanced by a concomitant
inﬁltration by CD66bþ neutrophils (Fig. 6). Accordingly, colo-
rectal cancer samples with concomitant high inﬁltration by
CD66bþ and CD8þ T cells were more frequently characterized
by pN0 stage (absence of nodal metastases P ¼ 0.03), and a
more frequent "pushing" tumor border (P ¼ 0.038; Supple-
mentary Table S2).
Several models with additive inclusion of single clinical–
pathologic data were also tested. Age and gender of the patients
and pT or pN stages of the tumors did not affect the signiﬁcant
prognostic impact of CD66bþ and CD8þ cell inﬁltration.
However, when vascular invasion or invasive margins were
added to the model, colorectal cancer inﬁltration by CD66bþ
and CD8þ cells lost its independent prognostic value (data not
shown).
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Discussion
The role of neutrophils in tumor immunobiology and the
prognostic signiﬁcance of neutrophil inﬁltration in cancer tissues
are controversial (1, 2). Early studies have documented a direct
cytotoxic potential of neutrophils against deﬁned tumor cell lines
(29). However, granulocytes have also been shown to actively
contribute to the generation of microenvironmental conditions
favoring tumor growth, particularly in cancers associated with
chronic inﬂammation. Their ability to degrade extracellular
matrix and to promote angiogenesis has been shown to play
critical roles in tumor progression (32). More recently, neutro-
phils were shown to accumulate in premetastatic niches with pro-
or antitumor functions in different experimentalmodels (33, 34).
Importantly, the ability of neutrophils at different maturation
stages to suppress immune responses has been clearly demon-
strated in experimental model (35, 36). However, the phenotypic
and functional characterization of human MDSC of the granu-
locytic lineage has not been elucidated in comparable detail (37).
Recent studies suggest that local microenvironmental conditions
might result in the polarization of neutrophils toward pro- or
antitumor functional states (38), possibly characterized by dif-
ferent physical and functional proﬁles (36). Remarkably, depend-
ing on anatomical locations and histologic origins, human can-
cers may be characterized by highly diverse microenvironmental
conditions, potentially impacting on the clinical signiﬁcance of
granulocyte inﬁltration.
In this study, we report that the analysis of a large clinically
annotated TMA including over 600 colorectal cancer reveals that
CD66bþ cell inﬁltration is associated with favorable prognosis.
CD66b is expressed by neutrophils and eosinophils. However, in
keeping with previously published data (39), we observed that
>90% of CD66bþ colorectal cancer–inﬁltrating cells were neu-
trophils. Although colorectal cancer appears to be inﬁltrated to a
larger extent than autologous adjacent healthy tissue, phenotypic
proﬁles of colorectal cancer–inﬁltrating neutrophils largelymatch
those detectable in healthymucosa–inﬁltrating cells. However, in
agreement with data regarding early lung cancer–inﬁltrating neu-
trophils (12, 13), TANs appear to express CD54 to higher extents
as compared with neutrophils inﬁltrating autologous adjacent
healthy mucosa, consistent with an "activated" phenotypic
proﬁle.
Mechanisms potentially underlying the favorable prognostic
signiﬁcance of colorectal cancer inﬁltration by CD66bþ cells
were investigated in detail. Our results indicate that coculture
with autologous neutrophils enhances T-cell receptor–triggered
activation of CD8þ T cells and may promote the expansion of a
lymphocyte subset characterized by the expression of "memo-
ry" markers. The relevance of these ﬁndings to colorectal cancer
immunobiology is indirectly supported by the colocalization of
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neutrophils and both CD8þ and CD45ROþ T cells in colorectal
cancer tissues. Furthermore, most importantly, colorectal can-
cer concomitantly inﬁltrated by neutrophils and CD8þ T cells
are characterized by a signiﬁcantly more favorable prognosis, as
compared with tumors displaying high CD8þ but low CD66bþ
cell inﬁltration. High neutrophil inﬁltration "per se," in the
absence of concomitant CD8þ lymphocytes, provided a more
modest, but still highly signiﬁcant, prognostic advantage as
compared with colorectal cancer where neither high-density
CD8þ nor CD66bþ inﬁltrates were detectable. Therefore,
absence of lymphocyte inﬁltration or inﬁltration by "unfavor-
able" T cells might prevent a full elicitation of antitumor effects
of neutrophils.
These data may suggest that the favorable prognostic signiﬁ-
cance of inﬁltration by neutrophils in colorectal cancer might, at
least in part rely on their interaction with CD8þ T cells, possibly
based on costimulatorymechanisms, as suggested byour "in vitro"
results. Admittedly, literature reports based on "in vitro" studies
with human cells in this area are controversial (30, 40, 41).
However, in our experience, different techniques, and, in partic-
ular, the use of human, as opposed to calf serum, might largely
account for the observed discrepancies.
The potential relevance of these results might obviously extend
beyond colorectal cancer immunobiology. Neutrophil–CD8þ T-
cell interactions might indeed be operational in a wider range of
conditions, thus supporting the notion of a highly effective
cooperation between innate and adaptive immune responses.
Remarkably, similar results have also emerged from studies
conducted in experimental models (42) and in clinical settings,
including early-stage lung cancer (12, 13) and autoimmune and
infectious disease (31). Underlying molecular mechanisms have
not been fully clariﬁed. In particular, cell–cell interactions medi-
ated by OX40, CD58, CD59, and their ligands have been pro-
posed (12, 31). Alternatively, a role for ROS release has also been
suggested (42). Our data suggest that CD11a/CD54 interaction
powerfully contributes to the elicitation of the costimulatory
effects of neutrophils on CD8þ T-cell activation. Nevertheless,
further research is warranted to obtain additional mechanistic
insights.
Overall, an important limitation in studies on TANs is repre-
sented by their short life span, high sensitivity to enzymes nec-
essary for the generation of single-cell suspensions from clinical
specimens and relatively low numbers, preventing the routine
performance of functional studies. However, the consistency of
"in vitro" results data emerging by using TANs, and PBNs from
patients with colorectal cancer and HDs together with the clinical
data, appears to support the notion of a potentially high relevance
of neutrophil–T-cell interaction on tumor sites.
Our study suffers from a number of additional limitations
largely inherent in research requiring the use of clinical materials.
Reported clinical data stem from a retrospective study. However,
performance of prospective studies, currently being planned, is
delayed by overall survival rates in patients with colorectal cancer
frequently exceeding 50% at 5 years following surgery. Further-
more, repeated biopsies of metastatic sites are usually not includ-
ed in routine clinical procedures. Therefore, the performance of
longitudinal studies addressing the role of neutrophils in different
stages of tumor progression is problematic. Finally, numbers of
neutrophils andCD8þ T cells whichmay be obtained from freshly
excised colorectal cancer are usually modest and barely amenable
to standard cellular immunology assays, particularly in autolo-
gous settings. For instance, direct tumor cytotoxicity studies could
only performed with resting or activated peripheral blood neu-
trophils from patients and HDs and we were unable to separate
sufﬁcient numbers of high/normal and low-density granulocytes
(36) from tumor suspensions.
Remarkably, our results also appear to suggest functional
discrepancies between PBN and autologous TAN as regarding,
for instance, the capacity of expanding "central memory" cells.
These data urge further research aimed at clarifying whether these
discrepancies are due to functional impairments of TAN in speciﬁc
tumor microenvironments (7) or to tumor inﬁltration by CD66þ
cell subpopulations of different functional signiﬁcance (36, 37).
Our study also poses a number of additional important ques-
tions. The fact that in a variety of tumors other than colorectal
cancer, neutrophil inﬁltration has been suggested to be associated
with poor prognosis (35, 43, 44) raises the issue of the speciﬁcities
inherent in neutrophil inﬁltration in colorectal cancer. The
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microenvironment of these tumors presents a variety of peculiar
characteristics. Similar to other cancers (45), colorectal cancer
inﬁltration by "memory" CD8þ T cells has been shown to be
associated with favorable prognosis. However, tumor inﬁltration
by cells expressing FOXP3, a classical regulatory T-cellmarker, also
appears to correlate with a less severe clinical course (46). Fur-
thermore, at difference with tumors of different histologic origin
(20) colorectal cancer inﬁltration by macrophages is also associ-
ated with favorable prognosis (21). Most remarkably, colorectal
cancer cells have previously been shown (47) to produceGM-CSF,
possibly enhancing viability and functions of granulocytes even-
tually recruited within tumor microenvironment.
Data regarding neutrophil inﬁltration in colorectal cancer
from East Asia patients (24) appear to contradict our results.
Genetic background may play an important role in this context.
However, additional factors might be involved in determining
the prognostic relevance of neutrophil inﬁltration. Colorectal
cancer oncogenesis is typically characterized by an early
increase in bacterial translocation from the gut lumen (48)
and gut microbiome composition has recently been shown to
decisively impact on chemo- and immunotherapy outcome
(49). Considering the key role of neutrophils in the response
to bacteria, it is tempting to speculate that microbiome com-
position might decisively affect their ability to actively partic-
ipate to antitumor immune response. Thus, differences in
human gut microbiome in different geographic areas (50)
might also be of importance in the evaluation of the prognostic
signiﬁcance of neutrophil inﬁltration in colorectal cancer.
Within this context, our data also urge studies aimed at the
clariﬁcation of mechanisms favoring the recruitment of gran-
ulocytes within colorectal cancer tissues.
In conclusion, our study, providing clear evidence of the
prognostic signiﬁcance of concomitant inﬁltration by CD8þ
cells and neutrophils in colorectal cancer, represents an addi-
tional example of clinically relevant interaction between non-
cancerous cells from the tumor microenvironment. Further-
more, it clearly identiﬁes neutrophils as key players in colo-
rectal cancer immunobiology.
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